Biodelivery Sciences International (BDSI) 10-K 15 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 13, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	BDSI
Entity Registrant Name	BIODELIVERY SCIENCES INTERNATIONAL INC
Entity Central Index Key	1,103,021
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		58,449,620
Entity Public Float			$ 124,774,588

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 21,195	$ 32,019
Accounts receivable, net	8,852	2,967
Inventory, net	6,091	3,368
Prepaid expenses and other current assets	3,610	4,136
Total current assets	39,748	42,490
Property and equipment, net	3,778	4,230
Goodwill	2,715	2,715
BELBUCA®license and distribution rights intangible asset, net	40,500
Other intangible assets, net	1,360	2,285
Total assets	88,101	51,720
Current liabilities:
Accounts payable and accrued liabilities	26,149	17,572
Deferred revenue, current		1,716
Total current liabilities	26,149	19,288
Notes payable	47,660	29,272
Deferred revenue, long-term		20,000
Other long-term liabilities	5,415	825
Total liabilities	79,224	69,385
Commitments and contingencies (Notes 6 and 17)
Stockholders' equity (deficit):
Preferred Stock, $.001 par value; 5,000,000 shares authorized; 2,093,155 shares of Series A Non-Voting Convertible Preferred Stock outstanding at both December 31, 2017 and 2016, respectively	2	2
Common Stock, $.001 par value; 75,000,000 shares authorized; 55,904,072 and 54,133,511 shares issued; 55,888,581 and 54,118,020 shares outstanding at December 31, 2017 and 2016, respectively	56	54
Additional paid-in capital	313,922	292,667
Treasury stock, at cost, 15,491 shares	(47)	(47)
Accumulated deficit	(305,056)	(310,341)
Total stockholders' equity (deficit)	8,877	(17,665)
Total liabilities and stockholders' equity (deficit)	$ 88,101	$ 51,720

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	55,904,072	54,133,511
Common Stock, shares outstanding	55,888,581	54,118,020
Treasury stock, shares	15,491	15,491
Series A Non-Voting Convertible Preferred Stock [Member]
Preferred Stock, shares outstanding	2,093,155	2,093,155

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Product sales	$ 34,922,000	$ 8,266,000	$ 4,157,000
Product royalty revenues	5,070,000	3,646,000	1,406,000
Research and development reimbursements	799,000	1,134,000	909,000
Contract revenue	21,194,000	2,500,000	41,759,000
Total revenues	61,985,000	15,546,000	48,231,000
Cost of sales	19,496,000	11,258,000	8,101,000
Expenses:
Research and development	13,040,000	18,878,000	20,624,000
Selling, general and administrative	58,869,000	49,345,000	54,685,000
Total expenses	71,909,000	68,223,000	75,309,000
Loss from operations	(29,420,000)	(63,935,000)	(35,179,000)
Interest expense, net	(8,577,000)	(3,267,000)	(2,518,000)
Bargain purchase gain	27,336,000
Other (expense) income, net	(26,000)	64,000	25,000
Loss before income taxes	(10,687,000)	(67,138,000)	(37,672,000)
Income tax benefit	15,972,000	0	0
Net income (loss) attributable to common stockholders	$ 5,285,000	$ (67,138,000)	$ (37,672,000)
Basic:
Weighted average common stock shares outstanding	55,355,802	53,679,134	52,384,876
Basic earnings (loss) per share	$ 0.10	$ (1.25)	$ (0.72)
Diluted:
Diluted weighted average common stock shares outstanding	56,402,479	53,679,134	52,384,876
Diluted earnings (loss) per share	$ 0.09	$ (1.25)	$ (0.72)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Series A Preferred Stock [Member]
Beginning Balance at Dec. 31, 2014	$ 54,396	$ 52	$ 259,920	$ (47)	$ (205,531)	$ 2
Beginning Balance, shares at Dec. 31, 2014		51,603,070				2,139,000
Stock-based compensation	14,249		14,249
Stock option exercise	$ 755		755
Stock option exercise, shares	235,480	223,923
Restricted stock awards	$ 1	$ 1
Restricted stock awards, shares		857,677
Warrant exercises	1		1
Warrant exercises, shares		284
Short swing profit return / Issuance of warrants	6		6
Conversion of preferred shares to common shares	0	$ 0	0	0	0	$ 0
Conversion of preferred shares to common shares, shares		45,845				(45,845)
Equity financing costs	(40)		(40)
Net income (loss)	(37,672)				(37,672)
Ending Balance at Dec. 31, 2015	31,696	$ 53	274,891	(47)	(243,203)	$ 2
Ending Balance, shares at Dec. 31, 2015		52,730,799				2,093,155
Stock-based compensation	14,931		14,931
Stock option exercise	$ 297		297
Stock option exercise, shares	147,425	147,426
Restricted stock awards, shares		592,065
Common stock issuance upon retirement	$ 2,460	$ 1	2,459
Common stock issuance upon retirement, shares		663,221
Short swing profit return / Issuance of warrants	49		49
Equity financing costs	40		40
Net income (loss)	(67,138)				(67,138)
Ending Balance at Dec. 31, 2016	(17,665)	$ 54	292,667	(47)	(310,341)	$ 2
Ending Balance, shares at Dec. 31, 2016		54,133,511				2,093,155
Stock-based compensation	14,801		14,801
Stock option exercise	$ 439		439
Stock option exercise, shares	202,519	202,519
Restricted stock awards		$ 2	(2)
Restricted stock awards, shares		1,568,042
Short swing profit return / Issuance of warrants	$ 6,017		6,017
Net income (loss)	5,285				5,285
Ending Balance at Dec. 31, 2017	$ 8,877	$ 56	$ 313,922	$ (47)	$ (305,056)	$ 2
Ending Balance, shares at Dec. 31, 2017		55,904,072				2,093,155

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating activities:
Net income (loss)	$ 5,285	$ (67,138)	$ (37,672)
Adjustments to reconcile net income (loss) to net cash flows from operating activities
Depreciation	693	437	329
Accretion of debt discount and loan costs	2,392	397	500
Amortization of intangible assets	5,425	971	970
Provision for inventory obsolescence	243	0
Stock-based compensation expense	14,801	14,931	14,249
Deferred income taxes	(15,972)
Bargain purchase gain	(27,336)
Changes in assets and liabilities:
Accounts receivable	(5,884)	(862)	670
Inventories	2,448	(810)	(730)
Prepaid expenses and other assets	526	(203)	(1,365)
Accounts payable and accrued expenses	6,644	(1,546)	5,055
Deferred revenue	(21,716)	(159)	14,262
Net cash flows used in operating activities	(32,451)	(53,982)	(3,732)
Investing activities:
BELBUCA® acquisition	(5,853)
Purchase of equipment	(11)	(405)	(701)
Net cash flows used in investing activities	(5,864)	(405)	(701)
Financing activities:
Proceeds from sales of securities, net of costs incurred		40	(40)
Proceeds from exercise of stock options	439	297	755
Issuance of common stock		2,460
Issuance of warrants		49
Proceeds from exercise of common stock warrants			1
Payment on note payable	(30,000)		(3,335)
Proceeds from notes payable	60,000		20,667
Return of short swing profits			6
Payment of deferred financing fees	(2,948)		(533)
Net cash flows from financing activities	27,491	2,846	17,521
Net change in cash and cash equivalents	(10,824)	(51,541)	13,088
Cash and cash equivalents at beginning of year	32,019	83,560	70,472
Cash and cash equivalents at end of year	21,195	32,019	83,560
Cash paid for interest	5,285	$ 2,870	$ 1,885
Non-cash Operating, Financing and Investing Activities:
Fair value of bargain purchase price of BELBUCA acquisition	27,300
Fair value of warrants, in connection with CRG term loan	$ 6,000
Series A Preferred Stock [Member]
Non-cash Operating, Financing and Investing Activities:
Series A Preferred stock converted			45,845

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Nature of Business and Summary of Significant Accounting Policies	1. Nature of business and summary of significant accounting policies: Organization BioDelivery Sciences International, Inc. and subsidiaries (the “Company”) was incorporated in the State of Indiana on January 6, 1997 and reincorporated as a Delaware corporation in 2002. The Company’s subsidiaries are Arius Pharmaceuticals, Inc., a Delaware corporation (“Arius One”) and Arius Two, Inc., a Delaware corporation (“Arius Two”), each of which are wholly-owned, and its majority-owned subsidiary, Bioral Nutrient Delivery, LLC, a Delaware limited liability company (“BND”). The Company is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. The Company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA ® As used herein, the Company’s common stock, par value $.001 per share, is referred to as the “Common Stock”. Principles of consolidation The consolidated financial statements include the accounts of the Company, Arius One, Arius Two and BND. For each period presented BND has been an inactive subsidiary. All significant inter-company balances and transactions have been eliminated. Significant accounting policies: Use of estimates in financial statements The preparation of the accompanying consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company reviews all significant estimates affecting the consolidated financial statements on a recurring basis and records the effect of any necessary adjustments prior to their issuance. Significant estimates of the Company include: revenue recognition, sales allowances such as returns of product sold, government program rebates, customer coupon redemptions, wholesaler/pharmacy discounts, product service fees, rebates and chargebacks, sales bonuses, stock-based compensation, determination of fair values of assets and liabilities relating to business combinations, and deferred income taxes. Reacquisition of BELBUCA ® On December 7, 2016, the Company entered into an agreement (the “Termination Agreement”) with Endo Pharmaceuticals, Inc. (“Endo”) terminating Endo’s licensing of rights to the Company’s BELBUCA ® ® ® ® Reclassification Certain amounts were reclassified between Accounts Receivable and Accounts Payable and Accrued Expenses for the year ended December 31, 2016 Consolidated Balance Sheet and in the Consolidated Statement of Cash Flows for the years ended December 31, 2016 and 2015 to conform to current year presentation to reflect the right of offset and practice of settling certain liabilities with our wholesale customers. Certain amounts were also reclassified between Accounts Payable and Accrued Liabilities in note 3, for the year ended December 31, 2016 to conform to current year presentation. The Company also reclassified certain amounts between Machinery & Equipment and Idle Equipment in note 4, for the year ended December 31, 2016. These reclassifications had no effect on the previously reported net cash flows from operations, activities or net losses. Certain risks, concentrations and uncertainties The Company relies on certain materials used in its development and third-party manufacturing processes, most of which are procured from three contract manufacturers and two active pharmaceutical ingredient (“API”) suppliers for BELBUCA ® ® ® ® In addition, the Company utilizes only two contract manufacturers to create the BELBUCA ® ® ® ® Key components used in the manufacture of ONSOLIS ® The Company sells its BELBUCA ® ® December 31, Customers 2017 2016 Customer A 47 % 36 % Customer B 22 % 28 % Customer C 26 % 28 % Total 95 % 92 % These three customers accounted for 92%, 91% and 90% of total annual sales during the years ended December 31, 2017, 2016 and 2015 respectively. Cash The Company places cash on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation covers $0.25 million for substantially all depository accounts. As of December 31, 2017, the Company had approximately $21.2 million, which exceeded these insured limits. As of December 31, 2016, the Company had approximately $32.0 million, which exceeded these insured limits. Accounts receivable The Company typically requires its customers to remit payments within the first 30 to 37 days, depending on the customer and the products purchased. In addition, the Company offers wholesale distributors a prompt payment discount if they make payments within these deadlines. This discount is generally 2% but may be higher in some instances due to product launches or customer and/or industry expectations. Because the Company’s wholesale distributors typically take the prompt payment discount, the Company accrues 100% of the prompt payment discounts, based on the gross amount of each invoice, at the time of sale, and the Company applies earned discounts at the time of payment. The allowance for prompt payment discounts was $0.2 million and $0.05 million as of December 31, 2017 and 2016, respectively. The Company performs ongoing credit evaluations and does not require collateral. As appropriate, the Company establishes provisions for potential credit losses. As such, there were no allowances for doubtful accounts as of December 31, 2017 or 2016. The Company writes off accounts receivable when management determines they are uncollectible and credits payments subsequently received on such receivables to bad debt expense in the period received. Write-offs during the years ending December 31, 2017, 2016 and 2015 were $0, $0.02 million and $0, respectively. Inventory Inventories are stated at the lower of cost or net realizable value with costs determined for each batch under the first-in, first-out On a quarterly basis, the Company analyzes its inventory levels and records allowances for inventory that has become obsolete, inventory that has a cost basis more than the expected net realizable value and inventory that is more than expected demand based upon projected product sales. The Company recorded $0.2 million in inventory obsolescence as of December 31, 2017. There were no allowances recorded as of December 31, 2016. Inventory is composed of the following at December 31: 2017 2016 Raw Materials & Supplies $ 1,338 $ 978 Work-in-process 3,135 1,660 Finished Goods 1,861 730 Finished Goods Reserve (243 ) — Total Inventories $ 6,091 $ 3,368 Property and equipment The Company records property and equipment at cost less accumulated depreciation, which is computed on a straight-line basis over its estimated useful lives, generally 3 to 10 years. The Company evaluates the carrying value of the idle equipment when events or changes in circumstances indicate the related carrying amount may not be recoverable. During the year ended December 31, 2017, $0.7 million of idle equipment was placed back into production to support manufacturing of BELBUCA ® ® re-tooled, ® Intangibles and goodwill The Company reviews intangible assets with finite lives (“other intangible assets”) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company uses an estimate of the undiscounted cash flows over the remaining life of its other intangible assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment. There were no impairment charges recognized on finite lived intangibles in 2017, 2016 or 2015. Intangible assets with finite useful lives are amortized over the estimated useful lives as follows: Estimated Licenses 15 years BELBUCA ® 10 years U.S. product rights 8-12 years EU product rights 7-11 Goodwill is evaluated for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. During the evaluation of the potential impairment of goodwill, either a qualitative or a quantitative assessment may be performed. If a qualitative evaluation determines that it is more likely than not that no impairment exists, then no further analysis is performed. If a qualitative evaluation is unable to determine whether it is more likely than not that impairment has occurred, a quantitative evaluation is performed. If the carrying value exceeds the fair value, an impairment charge is recorded based on that difference. There were no goodwill impairment charges in 2017, 2016 or 2015. Deferred revenue Consistent with the Company’s revenue recognition policy, deferred revenue represents cash received in advance for licensing fees, consulting, research and development services and related supply agreements. Such payments are reflected as deferred revenue until recognized under the Company’s revenue recognition policy. Deferred revenue is classified as current if management believes the Company will be able to recognize the deferred amount as revenue within twelve months of the balance sheet date. Deferred revenue is recognized when the product is sold to the end user, based upon prescriptions filled. To estimate product sold to end users, the Company relies on third-party information, including prescription data and information obtained from significant distributors with respect to their inventory levels and sales to customers. Deferred revenue is recorded net of estimated allowances for rebates, price adjustments, chargebacks, prompt payment and other discounts. Estimated allowances are recorded and classified as accrued expenses in the accompanying balance sheets as of December 31, 2017 and 2016 (see note 3). The Company deferred sales, until January 1, 2017, of BUNAVAIL ® ® Revenue recognition Net product sales Beginning in the first quarter of 2017, the Company had determined that it had sufficient experience with BELBUCA ® ® ex-factory ® ® can reasonably estimate the amount of future product returns, and therefore, the risk of estimating product returns has been substantially eliminated. The effect in income from operations and on net income is that the Company can recognize revenue earlier on the sell-in The Company establishes allowances for estimated rebates, chargebacks and product returns based on numerous qualitative and quantitative factors, including: • the number of and specific contractual terms of agreements with customers; • estimated levels of inventory in the distribution channel; • historical rebates, chargebacks and returns of products; • direct communication with customers; • anticipated introduction of competitive products or generics; • anticipated pricing strategy changes by the Company and/or its competitors; • analysis of prescription data gathered by a third-party prescription data provider; • the impact of changes in state and federal regulations; and • the estimated remaining shelf life of products. In its analyses, the Company uses prescription data purchased from a third-party data provider to develop estimates of historical inventory channel sell-through. The Company utilizes an internal analysis to compare historical net product shipments to estimated historical prescriptions written. Based on that analysis, management develops an estimate of the quantity of product in the channel which may be subject to various rebate, chargeback and product return exposures. To estimate months of ending inventory in the Company’s distribution channel, the Company divides estimated ending inventory in the distribution channel by the Company’s recent prescription data, not considering any future anticipated demand growth beyond the succeeding quarter. Monthly for each product line, the Company prepares an internal estimate of ending inventory units in the distribution channel by adding estimated inventory in the channel at the beginning of the period, plus net product shipments for the period, less estimated prescriptions written for the period. This is done for each product line by applying a rate of historical activity for rebates, chargebacks and product returns, adjusted for relevant quantitative and qualitative factors discussed above, to the potential exposed product estimated to be in the distribution channel. Product returns 18-month Rebates Price adjustments and chargebacks The Company, from time to time, offers certain promotional product-related incentives to its customers. These programs include certain product incentives to pharmacy customers and other sales stocking allowances. The Company has voucher programs for BELBUCA ® ® point-of-sale Prompt payment discounts Gross to net accruals License and development agreements The Company periodically enters into license and development agreements to develop and commercialize its products. The arrangements typically are multi-deliverable arrangements that are funded through upfront payments, milestone payments and other forms of payment. The Company currently has multiple license and development agreements that are described in notes 6, 8 and 9. Depending on the nature of the contract these revenues are classified as research and development reimbursements or contract revenue. Deferred cost of sales Prior to January 1, 2017, the Company deferred its cost of sales relating to BUNAVAIL ® ex-factory ® ® The Company incurred $1.7 million of deferred costs of sales for the year ended December 31, 2016, which is included in other current assets in the accompanying balance sheets. There was no deferred cost of sales for the year ended December 31, 2017. Cost of sales Cost of sales includes the direct costs attributable to the production of BELBUCA ® ® ® ® For BREAKYL ™ ™ out-licensed Research and development expenses Research and development expenses consist of product development expenses incurred in identifying, developing and testing product candidates. Product development expenses consist primarily of labor, benefits and related employee expenses for personnel directly involved in product development activities; fees paid to professional service providers for monitoring and analyzing clinical trials; expenses incurred under joint development agreements; regulatory costs; costs of contract research and manufacturing of inventory used in testing and clinical trials; and the cost of facilities used by the Company’s product development personnel. Product development expenses are expensed as incurred and reflect costs directly attributable to product candidates in development during the applicable period and to product candidates for which the Company has discontinued development. Additionally, product development expenses include the cost of qualifying new current Good Manufacturing Practice (“cGMP”) third-party manufacturers for the Company’s product candidates, including expenses associated with any related technology transfer. All indirect costs (such as salaries, benefits or other costs related to the Company’s accounting, legal, human resources, purchasing, information technology and other general corporate functions) associated with individual product candidates are included in general and administrative expenses. Research and development expenses were $13.0 million, $18.9 million and $20.6 million for the years ended December 31, 2017, 2016 and 2016 respectively. Advertising Advertising costs, which include promotional expenses and the cost of placebo samples, are expensed as incurred. Advertising expenses were $3.8 million, $4.2 million and $4.9 million for the years ended December 31, 2017, 2016 and 2015, respectively, and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations. Shipping and handling costs Shipping and handling costs, which include expenses from our wholesalers, are expensed as incurred. Shipping and handling costs were $0.2 million, $0.05 and $0.05 million for the years ended December 31, 2017, 2016 and 2015, respectively, and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations. Stock-based compensation The Company has a stock-based compensation plan under which various types of equity-based awards are granted, including stock options, restricted stock units (RSUs) and performance-based RSUs. The fair value of stock option and RSUs, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. Forfeitures are recognized as they occur. The fair values of performance-based RSUs are recognized as compensation expense from the grant date to the end of the performance period. The Company uses the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (warrants and options). The grant date fair value of an RSU equals the closing price of our common stock on the trading day preceding the grant date. The fair value of each option and warrant is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on historical volatility of the Company’s Common Stock and other factors estimated over the expected term of the options. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield. In applying the Black-Scholes options-pricing model, assumptions are as follows: 2017 2016 2015 Expected price volatility 68.76%-78.79% 62.65%-80.78% 73.00%-76.78% Risk-free interest rate 1.77%-2.05% 0.56%-1.70% 1.25%-1.68% Weighted average expected life in years 6 years 6 years 6 years Dividend yield — — — The Company estimated fair values of derivative financial instruments using the Black-Scholes option valuation technique because it embodied all of the requisite assumptions (including trading volatility, estimated terms and risk-free rates) necessary to fairly value these instruments. In addition, option-based techniques were highly volatile and sensitive to changes in the Company’s trading market price which was high-historical volatility. Since derivative financial instruments were initially and subsequently carried at fair values, the Company’s operating results reflected the volatility in these estimates and assumption changes. Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2014-09, 2015-14, 2014-09 2014-09 The Company used the modified retrospective approach upon adoption of this guidance effective January 1, 2018 using a cumulative effect adjustment to accumulated deficit. The Company utilized a comprehensive approach to assess the impact of the guidance on its contract portfolio. The Company reviewed its current accounting policies and practices to identify potential differences resulting from the application of the new requirements to its revenue contracts, including evaluation of performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each separate performance obligation and accounting treatment of costs to obtain and fulfill contracts. In addition, the Company will update certain disclosures, as applicable, included in our financial statements to meet the requirements of the new guidance beginning in January 1, 2018. Under the new guidance, the Company is required to evaluate the impact of estimating variable consideration related to our product sales and licensing contracts. The Company will use the expected value method to estimate the total revenue of the contract, constrained by the probability that there would not be a significant revenue reversal in a future period. The Company will continue to evaluate the expected value of revenue over the term of the contract and adjust revenue recognition as appropriate. Based on this evaluation, the adoption will not have a material impact on the Company’s financial position, results of operations, cash flows, accounting policies, business processes, internal controls or disclosures. The FASB’s new leases standard, ASU 2016-02 2016-02 right-of-use In January 2017, the FASB issued ASU 2017-01, Business In January 2017, the FASB issued ASU Update No. 2017-04, Intangibles—Goodwill in-process 2017-04

Liquidity

Liquidity	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Liquidity	2. Liquidity: At December 31, 2017, the Company had cash of approximately $21.2 million. The Company used $32.5 million of cash in operations during the year-ended December 31, 2017 and had stockholders’ equity of $8.9 million, versus stockholders’ deficit of $17.7 million at December 31, 2016. The Company expects that it has sufficient cash to manage the business as currently planned into the second quarter of 2019, which includes access to additional capital through CRG Servicing LLC (“CRG”) from the CRG loan of $15 million if it satisfies the third draw requirements (see note 11) as well as equity markets if the Company chooses or a combination of both that would provide sufficient capital necessary to support the commercialization of BELBUCA ® ® ® at-the-market Additional capital will be required to support the continued commercialization of the Company’s BELBUCA ® ® ®

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	3. Accounts payable and accrued liabilities: The following table represents the components of accounts payable and accrued liabilities as of December 31: 2017 2016 Accounts payable $ 12,236 $ 9,397 Accrued rebates 5,648 3,842 Accrued compensation and benefits 3,472 2,052 Accrued acquisition costs 2,311 — Accrued returns 915 — Accrued royalties 488 518 Accrued clinical trial costs 234 615 Accrued legal 216 490 Accrued manufacturing costs — 200 Accrued sales and marketing costs — 193 Accrued other 629 265 Total accounts payable and accrued expenses $ 26,149 $ 17,572 As of December 31, 2017, three vendors comprised 39% of the accounts payable balance. As of December 31, 2016, two vendors comprised 28% of the accounts payable balance.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	4. Property and equipment: Property and equipment, summarized by major category, consist of the following as of December 31: 2017 2016 Machinery & equipment $ 5,428 $ 4,476 Computer equipment & software 399 464 Office furniture & equipment 169 202 Leasehold improvements 44 53 Idle equipment 766 1,486 Total 6,806 6,681 Less accumulated depreciation (3,028 ) (2,451 ) Total property, plant & equipment, net $ 3,778 $ 4,230 Depreciation expense for years ended December 31, 2017, 2016 and 2015 was approximately $0.7 million, $0.4 million and $0.3 million, respectively.

Other Intangible Assets

Other Intangible Assets	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Other Intangible Assets	5. Other intangible assets: Other intangible assets, net, consisting of product rights and licenses are summarized as follows: December 31, 2017 Gross Carrying Accumulated Intangible Assets, Weighted average Product rights $ 6,050 $ (4,881 ) $ 1,169 1.21 BELBUCA ® 45,000 (4,500 ) 40,500 8.50 Licenses 1,900 (1,709 ) 191 0.54 Total intangible assets $ 52,950 $ (11,090 ) $ 41,860 10.25 December 31, 2016 Gross Carrying Accumulated Intangible Assets, Weighted average Product rights $ 9,050 $ (7,052 ) $ 1,998 9.11 Licenses 1,900 (1,613 ) 287 1.84 Total intangible assets $ 10,950 $ (8,665 ) $ 2,285 10.95 The Company incurred amortization expense on other intangible assets of approximately $5.4 million, $1.0 million and $1.0 million for the years ended December 31, 2017, 2016 and 2015, respectively. Estimated aggregate future amortization expenses for other intangible assets for each of the next five years and thereafter are as follows: Years ending December 31, 2018 $ 5,157 2019 5,157 2020 4,547 2021 4,500 2022 4,500 Thereafter 17,999 $ 41,860

License and Development Agreeme

License and Development Agreements	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
License and Development Agreements	6. License and development agreements: The Company periodically enters into license and development agreements to develop and commercialize its products. The arrangements typically are multi-deliverable arrangements that are funded through upfront payments, milestone payments, royalties and other forms of payment to the Company. The Company’s most significant license and development agreements are as follows: Meda license, development and supply agreements In August 2006 and September 2007, the Company entered into certain agreements with Meda AB (“Meda”) a subsidiary of Mylan N.V., a Swedish company to develop and commercialize the Company’s ONSOLIS ® ® The Company has determined that it is acting as a principal under the Meda Agreements and, as such, will record product supply revenue, research and development services revenue and other services revenue amounts on a gross basis in the Company’s consolidated financial statements. On March 12, 2012, the Company announced the postponement of the U.S. relaunch of ONSOLIS ® ® On January 27, 2015, the Company announced that it had entered into an assignment and revenue sharing agreement with Meda to return to the Company the marketing authorization for ONSOLIS ® ® Simultaneously on May 11, 2016, the Company and Collegium executed a definitive License and Development Agreement (the “License Agreement”) under which the Company had granted to Collegium the exclusive rights to develop and commercialize ONSOLIS ® Collegium license and development agreement On May 11, 2016, the Company and Collegium executed a License Agreement under which the Company granted Collegium the exclusive rights to develop and commercialize ONSOLIS ® Under the terms of the License Agreement, Collegium was responsible for the manufacturing, distribution, marketing and sales of ONSOLIS ® ® ® ® On December 8, 2017, the Company received the required 90-day notice ® Pursuant to the Collegium Agreement, the Company has received the following payments: • a $2.5 million upfront non-refundable • reimbursement to the Company for a pre-determined ® ONSOLIS ® ® ® ® ® Endo license and development agreement In January 2012, the Company entered into a License and Development Agreement with Endo Pharmaceuticals, Inc. (“Endo”) pursuant to which the Company granted Endo an exclusive commercial world-wide license to develop, manufacture, market and sell the Company’s BELBUCA ® ® around-the-clock, Pursuant to the Endo Agreement, Endo had obtained all rights necessary to complete the clinical and commercial development of BELBUCA ® ® ® ® ® Pursuant to the Endo Agreement, the Company has received the following recent payments: • $10 million upon FDA acceptance of filing NDA (earned in February 2015); • $50 million upon regulatory approval, earned in October 2015 and received in November 2015. Of the $50 million received in November 2015, $20 million related to a patent extension and was recorded as deferred revenue because all or a portion of such $20 million was contingently refundable to Endo if a third party generic product was introduced in the U.S. during the patent extension period from 2020 to 2027. However, due to the Company and Endo entering into a Termination Agreement on December 7, 2016 which terminated the BELBUCA ® ® The Company had assessed its arrangement with Endo and the Company’s deliverables thereunder at inception to determine: (i) the separate units of accounting for revenue recognition purposes, (ii) which payments should be allocated to which of those units of accounting and (iii) the appropriate revenue recognition pattern or trigger for each of those payments. The assessment requires subjective analysis and requires management to make judgments, estimates and assumptions about whether deliverables within multiple-element arrangements are separable and, if so, to determine the amount of arrangement consideration to be allocated to each unit of accounting. The Company was reimbursed by Endo for certain research and development costs when these costs went beyond set thresholds as outlined in the Endo Agreement. Endo reimbursed the Company for this spending at cost and the Company received no mark-up On October 26, 2015, the Company and Endo announced that the FDA approved BELBUCA ® ® pre-payments ® ®

Business Combination and BELBUC

Business Combination and BELBUCA Acquisition	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Business Combination and BELBUCA Acquisition	7. Business combination and BELBUCA ® On December 7, 2016, the Company and Endo entered into the Termination Agreement to terminate Endo’s licensing rights for BELBUCA ® ® work-in-progress, ® ® ® ® (v) all pre-approval regulatory ® of work-in-progress inventory, At the closing date, the Company accepted transfer of the net assets and assumed and agreed to discharge when due all applicable liabilities assumed by the Company, which consisted of post-closing obligations for liabilities and payments associated with the net assets, the assumed contracts related to the net assets and applicable taxes (with the obligation for pre-closing non-compete At the closing date, the Company and Endo entered into a Transition Services Agreement which governed the post-closing rights and responsibilities of the Company and Endo in connection with the license termination and the transfer of the Assets to the Company. Under this agreement, the Company and Endo agreed to the handling of transition matters such as managing customer contracts, BELBUCA ® ® The BELBUCA ® ® The following table summarizes the consideration paid to acquire BELBUCA ® Asset purchase price: Deferred cash consideration to Endo $ 7,536 Total asset purchase price $ 7,536 Estimated fair value of assets acquired: Current BELBUCA ® work-in $ 5,412 BELBUCA ® 432 License and distribution rights intangible assets 45,000 Deferred tax liability (15,972 ) Amount attributable to assets acquired $ 34,872 Bargain purchase gain $ (27,336 ) Inventories acquired included raw materials, work-in-progress work-in-process, The fair value of the equipment was determined by consideration of replacement cost and equipment condition and was assigned a useful life of seven years. The fair value of the license and distribution rights intangible assets as amortized in the accompanying consolidated balance sheets were estimated primarily using the “income method,” which starts with a forecast of all expected future cash flows. Some of the more significant assumptions inherent in the development of intangible asset values, from the perspective of a market participant, include: the amount and timing of projected future cash flows (including net revenue, cost of sales, commercial expenses, research and development costs and working capital requirements) as well as estimated contributory asset charges; the discount rate selected to measure the risks inherent in the future cash flows; and the assessment of the asset’s life cycle and the competitive trends impacting the asset, among other factors. The license and distribution rights intangible assets will be amortized over ten years, which approximates the current, remaining patent life of the BELBUCA ® As a result of the business combination, the Company recognized a deferred tax liability of $16.0 million. This deferred tax liability was netted against its deferred tax assets as of December 31, 2017. Because a full valuation allowance has been provided against the Company’s deferred tax assets as it is considered more likely than not that they will not be utilized, the Company released a corresponding amount of its valuation allowance during the year ended December 31, 2017 and recognized a $16.0 million tax benefit in the accompanying consolidated statement of operations. During the year ended December 31, 2017, the Company recorded the asset acquisition as a bargain purchase gain of $27.3 million in the accompanying consolidated statement of operations. Pro forma impact of acquisition of BELBUCA ® The following pro forma combined results of operations are provided for the year ended December 31, 2016, as though the BELBUCA ® ® ® (in thousands, except per share data) December 31, Revenue $ 25,010 Net loss $ (201,769 ) Pro forma net loss per common share Basic $ (3.76 ) Diluted $ (3.76 ) The Company’s historical financial information was adjusted to give effect to the pro forma events that were directly attributable to the BELBUCA ® • Adjustment to recognize incremental amortization expense based on the fair value of intangibles acquired; • Adjustment to recognize incremental depreciation expense for equipment acquired in the acquisition. Endo launched BELBUCA ®

License Obligations

License Obligations	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
License Obligations	8. License obligations: Arcion license agreement On March 26, 2013, the Company entered into a license agreement with Arcion Therapeutics, Inc. (the “Arcion Agreement”) pursuant to which Arcion granted to the Company an exclusive commercial world-wide license, with rights of sublicense, under certain patent and other intellectual property rights related to in-process On December 13, 2016, the Company announced that its Phase 2b clinical study assessing the efficacy and safety of Clonidine Topical Gel failed to show a statistically significant difference in pain relief between Clonidine Topical Gel and placebo. As a result, the Company has discontinued further development of the product as of December 31, 2016. Evonik definitive development and exclusive license option agreement: On October 27, 2014, the Company entered into a definitive Development and Exclusive License Option Agreement (the “Development Agreement”) with Evonik Corporation, (“Evonik”) to develop and commercialize an injectable, extended release, microparticle formulation of buprenorphine for the treatment of opioid dependence (the “Evonik Product”). Under the Development Agreement, the Company also has the right to pursue development of the Evonik Product for pain management. Under the Development Agreement, Evonik has also granted to the Company two exclusive options to acquire exclusive worldwide licenses, with rights of sublicense, to certain patents and other intellectual property rights of Evonik to develop and commercialize certain products containing buprenorphine. If these options are exercised, such licenses would be memorialized in the Evonik License Agreement (as defined below). Pursuant to the Development Agreement, Evonik is responsible for using commercially reasonable efforts to develop a formulation for the Evonik Product in accordance with a work plan mutually agreed upon by the parties (the “Evonik Project”). Should the Evonik Project proceed past the formulation stage, Evonik also has the right to manufacture clinical and commercial supplies of Evonik Product, such manufacturing arrangement to be negotiated by the parties in good faith in a formal License and Supply Agreement(s) (the “Evonik License Agreement”), with such Evonik License Agreement covering Evonik’s intellectual property rights to be entered into between the parties if certain conditions are met and terms are mutually agreed upon. Should Evonik and the Company enter into the License Agreement following the attainment of a Phase 1 ready formulation of the Evonik Product for one or both of the opioid dependence or pain management indications, the Company would pay Evonik a non-refundable, non-creditable one-time The Development Agreement contains customary termination provisions, and the Company may additionally terminate the Development Agreement at any time after the completion of certain enumerated tasks as provided in the Development Agreement, for any reason or no reason, by providing written notice of termination to Evonik. Upon termination of the Development Agreement, Evonik will be paid any amounts owed to Evonik in accordance with the estimated budget for work performed under the Development Agreement through the effective date of termination, including any reasonable, documented, non-cancelable This product candidate is currently in the pre-clinical

Other License Agreements and Ac

Other License Agreements and Acquired Product Rights	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Other License Agreements and Acquired Product Rights	9. Other license agreements and acquired product rights: Purdue license and supply agreement: On July 12, 2017, the Company, along with Purdue Pharma, an Ontario limited partnership (“Purdue”), announced that they had executed an exclusive agreement granting to Purdue the licensing, distribution, marketing and sale rights related to BELBUCA ® ® ® ® Pursuant to the agreement, the royalty from Purdue to the Company terminates on the later of (a) the first date on which there is not at least one valid claim of the licensed patents in the territory covering any licensed product or (b) February 14th of the calendar year immediately following the first complete calendar year following the tenth anniversary of first commercial sale in which net sales total less than a predetermined amount. On September 12, 2017, the Company announced Health Canada had granted market authorization to formally transfer the Drug Identification Number (DIN) ownership of BELBUCA ® On January 30, 2018, the Company and Purdue announced that BELBUCA ® ® Kunwha license agreement In May 2010, the Company entered into a License and Supply Agreement (the “Kunwha License Agreement”) with Kunwha to develop, manufacture, sell and distribute the Company’s BEMA ® ® ® Under the terms of the Kunwha License Agreement, Kunwha was granted exclusive licensing rights for BEMA ® TTY license and supply agreement On October 7, 2010, the Company announced a license and supply agreement with TTY Biopharm Co., Ltd. (“TTY”) for the exclusive rights to develop and commercialize BEMA ® ® On July 29, 2013, the Company announced the regulatory approval of BEMA ® ™ The Company received cumulative payments totaling $1.2 million and $0.9, all which related to royalties based on product purchased in Taiwan by TTY of PAINKYL ™ Agreement with Par Pharmaceuticals In conjunction with the aforementioned Endo Termination Agreement, on December 7, 2016, the Company also entered into a distribution agreement (the “Distribution Agreement”) with Par Pharmaceuticals, Inc. (“Par”) for the distribution of an authorized generic BELBUCA ® ® ® one-year two-year one-year ®

Note Payable (Midcap Loan)

Note Payable (Midcap Loan)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Note Payable (Midcap Loan)	10. Note payable (Midcap loan): On May 29, 2015, the Company entered into a $30 million secured loan facility (the “Loan”) with MidCap Financial Trust, as agent and lender (“MidCap”), pursuant to the terms and conditions of that certain Amended and Restated Credit and Security Agreement, dated as of May 29, 2015 (the “Credit Agreement”), between the Company and MidCap (the “MidCap Credit Agreement”). On February 21, 2017, the Company entered into a term loan agreement (the “Term Loan Agreement”) with CRG, as administrative agent and collateral agent, and the lenders named in the Term Loan Agreement (the “Lenders”). The Company utilized approximately $29.4 million of the initial loan proceeds under the Term Loan Agreement to repay all the amounts owed by the Company under the MidCap Credit Agreement. Upon the repayment of all amounts owed by the Company under the MidCap Credit Agreement, all commitments under the MidCap Credit Agreement were terminated and all security interests granted by the Company and its subsidiary guarantors under the MidCap Credit Agreement were released (see note 11, Term Loan Agreement (CRG)). Certain warrants issued to MidCap and its affiliates in May 2016 related to the extension of the interest only period under the MidCap Credit Agreement remain outstanding as of December 31, 2017 and will expire, if not earlier exercised in May 2021. Such warrants are exercisable for 84,986 shares of Common Stock at an exercise price of $3.53 per share. During the year ended December 31, 2017, $0.7 million of deferred loan costs arising out of the MidCap Credit Agreement were expensed and recorded as interest expense in the accompanying consolidated statement of operations.

Term Loan Agreement (CRG)

Term Loan Agreement (CRG)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Term Loan Agreement (CRG)	11. Term loan agreement (CRG): Pursuant to the Term Loan Agreement, the Company borrowed $45.0 million from the Lenders as of the Closing Date, and may be eligible to borrow up to an additional $30.0 million in two tranches of $15.0 million each contingent upon achievement of certain conditions, including: (i) in the case of the first tranche, representing the second potential draw under the Loan Agreement (the “Second Draw”), satisfying both (a) certain minimum net revenue thresholds on or before September 30, 2017 or December 31, 2017 and (b) a certain minimum market capitalization threshold for a period of time prior to the funding of the Second Draw (provided, that if the Company does not achieve the minimum net revenue thresholds necessary for the Second Draw but does achieve a certain minimum market capitalization threshold for a period of time prior to December 31, 2017, the Company would be eligible for a Second Draw funding in the amount of $5.0 million); and (ii) in the case of the second tranche, representing the third potential draw under the Loan Agreement (the “Third Draw”), satisfying both (a) certain minimum net revenue thresholds on or before June 30, 2018 or September 30, 2018 and (b) a certain minimum market capitalization threshold for a period of time prior to the funding of the Third Draw. On December 26, 2017, the Company was eligible and elected to receive the Second Draw for gross proceeds of $15.0 million. After the payoff of the MidCap Credit Agreement (see note 10), the Company is utilizing the initial proceeds under the Term Loan Agreement (after deducting loan origination costs and broker and other fees) of approximately $13.7 million, plus any additional amounts that may be borrowed in the future, for general corporate purposes and working capital. The Term Loan Agreement has a six-year term The Company may prepay all or a portion of the outstanding principal and accrued unpaid interest under the Term Loan Agreement at any time upon prior notice to the Lenders subject to a certain prepayment fees during the first five years of the term (which fees are lowered over time) and no prepayment fee thereafter. In certain circumstances, including a change of control and certain asset sales or licensing transactions, the Company is required to prepay all or a portion of the loan, including the applicable prepayment premium on the amount of the outstanding principal to be prepaid. As security for its obligations under the Term Loan Agreement, on the funding date of the initial borrowing, the Company and the Subsidiary Guarantors entered into a security agreement with CRG whereby the Company and the subsidiary guarantors of the Company under the Term Loan Agreement (the “Subsidiary Guarantors”) granted to CRG, as collateral agent for the Lenders, a lien on substantially all of its assets including intellectual property (subject to certain exceptions). The Term Loan Agreement requires the Company to maintain minimum cash and cash equivalents balance and, each year through the end of 2022, to meet a minimum net annual revenue threshold. The Company is in compliance as of December 31, 2017. In the event that the Company does not meet the minimum net annual revenue threshold, then the Company can satisfy the requirement for that year by raising two (2) times the shortfall by way of raising equity or subordinated debt. The Term Loan Agreement also contains customary affirmative and negative covenants for a credit facility of this size and type, including covenants that limit or restrict the Company’s ability to, among other things (but subject in each case to negotiated exceptions), incur indebtedness, grant liens, merge or consolidate, dispose of assets, make investments, make acquisitions, enter into transactions with affiliates, pay dividends or make distributions, license intellectual property rights on an exclusive basis or repurchase stock. The Term Loan Agreement includes customary events of default that include, among other things, non-payment, inaccuracy The following table represents future maturities of the CRG obligation as of December 31, 2017: 2018 $ — 2019 — 2020 20,054 2021 20,054 2022 20,054 Total maturities $ 60,162 Unamortized discount and loan costs (12,502 ) Total CRG obligation $ 47,660 In connection with the initial borrowing made under the Term Loan Agreement, the Company issued to CRG and certain of its affiliates five separate warrants to purchase an aggregate of 1,701,583 shares of the Common Stock (the “CRG Warrants”). The CRG Warrants are exercisable any time prior to February 21, 2027 at a price of $2.38 per share, with typical provisions for cashless exercises. The exercise of the CRG Warrants could have a dilutive effect to the Common Stock to the extent that the market price per share of the Common Stock, as measured under the terms of the CRG Warrants, exceeds the exercise price of the CRG Warrants. CRG is also entitled to receive a smaller amount of similar warrants concurrently with the funding, if applicable, of the Third Draw. In connection with the Second Draw, the Company issued to CRG and certain of its affiliates warrants to purchase an aggregate of 349,452 shares of the Company’s common stock (the “CRG Second Draw Warrants”). The CRG Second Draw Warrants are exercisable any time prior to December 26, 2027, at a price of $3.42 per share, with typical provisions for cashless exercise and stock-based anti-dilution protection. The exercise of the CRG Second Draw Warrants could have a dilutive effect to the Company’s common stock to the extent that the market price per share of the Company’s common stock, as measured under the terms of the CRG Second Draw Warrants, exceeds the exercise price of the CRG Warrants.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segment Reporting	12. Segment reporting: The Company operates in a single industry engaging in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. Accordingly, the Company’s business is classified as a single reportable segment. The following table presents net sales by product for each of the years ended December 31 (in thousands): Year ended December 31, 2017 2016 2015 BELBUCA ® $ 26,980 $ — $ — BUNAVAIL ® 7,942 8,266 4,157 Net product sales $ 34,922 $ 8,266 $ 4,157

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	13. Income taxes: On December 22, 2017, the United States enacted major tax reform legislation, Public Law No. 115-97, one-time On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Act. In accordance with SAB 118, the Company has determined that the $33.1 million of the deferred tax income offset by the reduction in valuation allowance recorded in connection with the re-measurement In addition, North Carolina reduced its corporate income tax rate from 4% to 3% in 2017. This resulted in a tax benefit of $1.7 million, offset by a reduction in the Company’s valuation allowance. The Company recorded an income tax benefit of $16.0 million in 2017. This benefit was associated with the release of the Company’s valuation allowance triggered by the recognition of deferred tax liabilities recorded as part of the Endo BELBUCA ® ® 2017 2016 2015 Federal statutory income (benefit) tax rate (34.00 %) 34.00 % 34.00 % 2017 Tax Act, net deferred tax remeasurement (626.73 ) — — State taxes, net of federal benefit (2.01 ) 2.88 3.45 Stock compensation (5.18 ) (0.61 ) — Permanent differences-other (13.39 ) (1.00 ) (4.66 ) North Carolina tax rate change (32.75 ) — — Research and development (“R&D”) credit 5.54 0.98 0.95 Valuation release for bargain purchase gain (302.23 ) — — Other (1.36 ) (0.47 ) 0.64 Decrease (increase) in valuation allowance 709.88 (35.78 ) (34.38 ) (302.23 %) 0.00 % 0.00 % The tax effects of temporary differences and net operating losses that give rise to significant components of deferred tax assets and liabilities consist of the following: December 31, Deferred tax assets (liabilities) 2017 2016 Deferred revenue $ — $ 7,377 Basis difference in equipment (587 ) (1,084 ) Basis difference in intangibles (8,288 ) 1,201 Accrued liabilities and other 654 550 R&D credit 11,882 11,589 AMT credit 79 79 Stock options 6,115 5,697 Net operating loss carry-forward 61,660 83,621 71,515 109,030 Less: valuation allowance (71,515 ) (109,030 ) $ — $ — The Company is required to reduce any deferred tax asset by a valuation allowance if, based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts, it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized. The valuation allowance should be sufficient to reduce the deferred tax asset to the amount which is more likely than not to be realized. As a result, the Company recorded a valuation allowance with respect to all of the Company’s deferred tax assets. The change in the valuation allowance for the year ended December 31, 2017 independent of the impact of the 2017 Tax Act was $(4.4 million). In addition to the remeasurement of the net deferred tax assets due to the 2017 Tax Act, the valuation allowance decreased in 2017 due primarily to changes in the intangible assets and deferred revenue offset partially by stock compensation and an increase in the Company’s net operating loss carryforwards. The Company has a federal net operating loss carry forward (“NOLs”) of approximately $263 million as of December 31, 2017. Under Section 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a “loss corporation”, as defined, there are annual limitations on the amount of the NOLs and other deductions which are available to the Company. The portion of the NOLs incurred prior to May 16, 2006 is subject to this limitation. As such, the use of these NOLs to offset taxable income is limited to approximately $1.5 million per year. The Company’s State NOLS are approximately $292 million as of December 31, 2017. These loss carryforwards expire between 2024 and 2037 for federal and 2030 for state purposes. Management has evaluated all other tax positions that could have a significant effect on the financial statements and determined that the Company has no uncertain income tax positions at December 31, 2017. One or more of the Company’s legal entities file income tax returns in the U.S. federal jurisdiction and various U.S. state jurisdictions. The Company’s income tax returns are subject to audit by the tax authorities in those jurisdictions. Significant disputes may arise with authorities involving issues of the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and the interpretation of the relevant facts. The Company is no longer subject to U.S. federal or state tax examinations for years ended on or before December 31, 2013.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' Equity	14. Stockholders’ equity: Common Stock On July 2, 2015, the Company filed a shelf registration statement which registered up to $150 million of the Company’s securities for potential future issuance, and such registration statement was declared effective on July 13, 2015. Concurrent with the filing of the registration statement, the Company established an “at-the-market” ® at-the-market On December 16, 2015, the Company and Dr. Andrew Finn entered into a retirement agreement (the “Retirement Agreement”) setting forth their mutual understandings regarding Dr. Finn’s retirement from the Company. Pursuant to the Retirement Agreement, all unvested RSUs previously issued under the Company’s equity incentive plans and held by Dr. Finn as of the retirement date were cancelled and, in lieu thereof, Dr. Finn was awarded a one-time Following its review of the Company’s corporate performance for 2015, the Compensation Committee of the Board of Directors approved in early 2016, equity awards for 2015 in the form of RSUs to its named executive officers (including Dr. Finn) and other senior executives in amounts at or below the 25th% percentile of the Company’s peer group. Dr. Finn, who retired on December 31, 2015, received an immediate award of 150,000 shares of Common Stock in fulfillment of the Company’s contractual obligation to him under the Retirement Agreement. Such shares were issued in March 2016. During the years ended December 31, 2017, 2016 and 2015, Company employees, directors and affiliates exercised approximately 0.2 million, 0.1 million and 0.2 million stock options, respectively, with net proceeds to the Company of approximately $0.4 million, 0.3 million and $0.8 million, respectively. Preferred Stock The Company had authorized five million “blank check” shares of $.001 par value convertible preferred stock. On December 3, 2012, the Company closed a registered direct offering, issuance and sale of Series A Preferred. The final amount of Series Preferred issued in the offering was an aggregate of 2,709,300 shares of Series A Preferred. In the event of the Company’s liquidation, dissolution or winding up, holders of the Series A Preferred will receive a payment equal to $.001 per share of Series A Preferred before any proceeds are distributed to the holders of common stock. After the payment of this preferential amount, and subject to the rights of holders of any class or series of capital stock hereafter created specifically ranking by its terms senior to the Series A Preferred, the holders of Series A Preferred will participate ratably in the distribution of any remaining assets with the common stock and any other class or series of our capital stock hereafter created that participates with the common stock in such distributions. At December 31, 2017, 2,093,155 shares of Series A Preferred were outstanding and 2,290,700 shares of “blank check” preferred stock remain authorized but undesignated. During the year ended December 31, 2015, 45,845 shares of Series A Preferred were converted to equal shares of the Company’s common stock. There were no conversions of Series A Preferred during the years ended December 31, 2017 or 2016. Restricted stock units During the year ended December 31, 2017, 2,357,315 RSUs, were granted to members of the Company’s executive officers, board of directors and employees, with a fair market value of approximately $4.7 million. The fair value of restricted units is determined using quoted market prices of the Common Stock and the number of shares expected to vest. These RSUs were issued under the Company’s 2011 Equity Incentive Plan, as amended, and vest as following: (i) For executive officers, half of the grant vests in equal installments over three years and the remaining half vests subject to performance criteria over three years, (ii) for employees, the grants vest in full June 2018, (iii) and for the board of directors grants vest one-half one-half Restricted stock activity during the year ended December 31, 2017 was as follows: Number of Weighted Outstanding at January 1, 2017 4,584,297 $ 7.29 Granted: Executive officers 1,640,000 1.85 Directors 162,315 2.80 Employees 555,000 2.10 Vested (1,568,042 ) 2.17 Forfeitures (666,675 ) 2.71 Outstanding at December 31, 2017 4,706,895 $ 5.20 Performance Long Term Incentive Plan In December 2012, the Company’s Board of Directors (the “Board”) approved the BDSI Performance Long Term Incentive Plan (“LTIP”). The LTIP is designed as an incentive for the Company’s senior management to generate revenue for the Company. The LTIP consists of RSUs (which are referred to in this context as Performance RSUs) which are rights to acquire shares of Common Stock. All Performance RSUs granted under the LTIP will be granted under the Company’s 2011 Equity Incentive Plan (as the same may be amended, supplemented or superseded from time to time) as “Performance Compensation Awards” under such plan. The participants in the LTIP are either named executive officers or senior officers of the Company. The term of the LTIP began with the Company’s fiscal year ended December 31, 2012 and lasts through the fiscal year ending December 31, 2019. The total number of Performance RSUs covered by the LTIP is 1,078,000, of which 978,000 were awarded in 2012 (with 100,000 Performance RSUs being reserved for future hires and of that reserve, 35,000 Performance RSUs were awarded in 2015). No additional Performance RSUs were awarded in 2016 or 2017. The Performance RSUs under the LTIP did not vest upon granting, but instead are subject to potential vesting each year over the 8-year pre-defined 10-K. Stock options The Company has a 2011 Equity Incentive Plan. During the 2017 Annual Meeting of Stockholders (the “Annual Meeting”), stockholders approved an amendment to the Company’s 2011 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance under the plan by 7,100,000 shares from 11,050,000 to 18,150,000. An additional 890,693 shares of Common Stock underlying options previously granted under the Company’s Amended and Restated 2001 Incentive Plan remain outstanding and exercisable as of December 31, 2017. The Company’s Amended and Restated 2001 Incentive Plan expired in July 2011 and no new securities may be issued thereunder. Options may be awarded during the ten-year Stock option activity for the years ended December 31, 2017, 2016 and 2015 is as follows: Number of Weighted Average Aggregate Outstanding at January 1, 2015 3,196,100 $ 4.32 $ 22,881 Granted in 2015: Others 684,629 8.14 Exercised (235,480 ) 3.52 Forfeitures (247,720 ) 12.65 Outstanding at December 31, 2015 3,397,529 $ 5.42 $ 3,124 Granted in 2016: Officers and Directors 95,000 $ 2.34 Others 558,373 3.12 Exercised (147,425 ) 2.01 Forfeitures (434,486 ) 13.17 Outstanding at December 31, 2016 3,468,991 $ 4.14 $ 0 Granted in 2017: Officers and Directors 83,658 $ 2.64 Others 873,017 1.96 Exercised (202,519 ) 2.17 Forfeitures (1,510,193 ) 5.13 Outstanding at December 31, 2017 2,712,954 $ 2.98 $ 1,190 Options outstanding at December 31, 2017 are as follows: Range of Exercise Prices Number Weighted Average Weighted Average Aggregate $1.00 – 5.00 2,192,695 5.53 $ 2.72 $5.01 – 10.00 430,149 5.38 $ 6.29 $10.01 – 15.00 48,358 7.14 $ 13.13 $15.01 – 20.00 41,500 6.75 $ 16.27 2,712,954 $ 1,190 Options exercisable at December 31, 2017 are as follows: Range of Exercise Prices Number Weighted Average Weighted Average Aggregate $1.00 – 5.00 1,400,022 3.48 $ 3.04 $5.01 – 10.00 345,257 5.43 $ 6.28 $10.01 – 15.00 35,439 7.13 $ 13.15 $15.01 – 20.00 41,500 6.75 $ 16.27 1,822,218 $ 561 The weighted average grant date fair value of options granted during the years ended December 31, 2017, 2016 and 2015 was $1.46, $1.75 and $4.99, respectively. There were no options granted during the years ended December 31, 2017, 2016 or 2015 whose exercise price was lower than the estimated market price of the stock at the grant date. Nonvested stock options as of December 31, 2017, and changes during the year then ended, are as follows: Nonvested Shares Shares Weighted Average Intrinsic Nonvested at January 1, 2017 829,431 Granted 960,175 Vested (363,701 ) Forfeited (540,421 ) Nonvested at December 31, 2017 885,484 $ 2.70 $ 629 As of December 31, 2017, there was approximately $5.5 million of unrecognized compensation cost related to unvested share-based compensation awards granted. These costs will be expensed over the next three years. Stock-based compensation During the year ended December 31, 2017, a total of 956,675 options to purchase Common Stock, with an aggregate fair market value of approximately $1.4 million, were granted to Company employees, directors and contractors. The options granted have a term of 10 years from the grant date and vest ratably between a one and three-year period. The fair value of each option is amortized as compensation expense evenly through the vesting period. The Company’s stock-based compensation expense is allocated between research and development and selling, general and administrative as follows as of December 31: Stock-based compensation expense 2017 2016 2015 Research and Development $ 1.6 $ 2.5 $ 4.2 Selling, General and Administrative $ 13.2 $ 12.4 $ 10.0 Warrants: The Company has granted warrants to purchase shares of Common Stock. Warrants may be granted to affiliates in connection with certain agreements. During the year ended December 31, 2016, the Company granted warrants to purchase 84,986 shares of Common Stock at an exercise price of $3.53 per share to Midcap and its affiliates in connection with the Company’s extension agreement with MidCap. The warrants were valued using the Black-Scholes Model, which fair value is approximately $0.05 million. As of December 31, 2017, 84,986 warrants remain outstanding. In February 2017, the Company granted warrants to purchase 1,701,583 shares of Common Stock at an exercise price of $2.38 per share to CRG and certain of its affiliates in connection with the Company’s term loan agreement with CRG. The warrants were valued using the Black-Scholes Model, which fair value is approximately $4.5 million. In December 2017, the Company granted warrants to purchase 349,451 shares of Common Stock at an exercise price of $3.42 per share to CRG and certain of its affiliates in connection with the Company’s 2 nd

Earnings per Common Share

Earnings per Common Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Earnings per Common Share	15. Earnings per common share: The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per common share computations for the years ended December 31, 2017, 2016 and 2015. December 31, 2017 2016 2015 Basic: Net income (loss) attributable to common stockholders $ 5,285 $ (67,138 ) $ (37,672 ) Weighted average common shares outstanding 55,355,802 53,679,134 52,384,876 Basic earnings (loss) per common share $ 0.10 $ (1.25 ) $ (0.72 ) Diluted: Effect of dilutive securities: Net income (loss) attributable to common stockholders 5,285 (67,138 ) (37,672 ) Adjustment to income for dilutive options and warrants — — — 5,285 (67,138 ) (37,672 ) Weighted average common shares outstanding 55,355,802 53,679,134 52,384,876 Effect of dilutive options and warrants 1,046,677 — — Diluted weighted average common shares outstanding 56,402,479 53,679,134 52,384,876 Diluted earnings (loss) per common share $ 0.09 $ (1.25 ) $ (0.72 ) Basic earnings per common share is calculated using the weighted average shares of Common Stock outstanding during the period. Common equivalent shares from stock options, RSUs, warrants and convertible preferred stock using the treasury stock method, are also included in the diluted per share calculations unless the effect of inclusion would be antidilutive. During the years ended December 31, 2017, 2016 and 2015, outstanding stock options, RSUs, warrants and convertible preferred stock of 6,531,346, 10,228,929 and 9,788,838, respectively, were not included in the computation of diluted earnings per common share, because to do so would have had an antidilutive effect because the outstanding exercise prices were greater than the average market price of the common shares during the relevant periods. The following is the total outstanding options, RSUs and warrants for the years ended December 31, 2017, 2016 and 2015, respectively. 2017 2016 2015 Options, RSUs, warrants and convertible preferred stock to purchase Common Stock 9,555,869 10,228,929 9,788,838

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Retirement Plan	16. Retirement plan: The Company sponsors a defined contribution retirement plan under Section 401(k) of the Internal Revenue Code. The plan covers all employees who meet certain eligibility and participation requirements. Participants may contribute up to 90% of their eligible earnings, as limited by law. The Company makes a matching contribution equal to 100% on the first 5% of participant contributions to the plan. The Company made contributions of approximately $0.5 million, $0.4 million and $0.2 million in years, 2017, 2016 and 2015.

Retirement agreements

Retirement agreements	12 Months Ended
	Dec. 31, 2017
Compensation Related Costs [Abstract]
Retirement agreements	17. Retirement agreements: Sirgo retirement agreement On August 23, 2017, Dr. Sirgo, the Company’s former President and Chief Executive Officer and current Vice Chairman, executed a retirement agreement (which is referred to as the Sirgo Retirement Agreement) memorializing the terms of Dr. Sirgo’s voluntary retirement from the Company, which was effective January 2, 2018 (which is referred to as the Sirgo Retirement Date, with the period from August 23, 2017 to the Sirgo Retirement Date being referred to herein as the Sirgo Transition Period). During the Sirgo Transition Period and following the Sirgo Retirement Date, Dr. Sirgo served and will continue to serve as Vice Chairman of the Company‘s board of directors. Pursuant to the Sirgo Retirement Agreement, Dr. Sirgo served as the Company’s President and Chief Executive Officer during the Sirgo Transition Period. By entering into the Sirgo Retirement Agreement, the Company and Dr. Sirgo agreed to terminate Dr. Sirgo’s employment agreement with the Company, dated August 24, 2004, as amended by that First Amendment thereto (collectively with the related confidentiality agreement between the Company and Sirgo, the Sirgo Employment Agreement) as of the Sirgo Retirement Date, subject to those provisions of the Sirgo Employment Agreement which survive termination (as the same were modified by the Sirgo Retirement Agreement), including provisions related to confidentiality, non-solicitation non-competition. In connection with his retirement from the Company, and in consideration of his many years of service to the Company (and in lieu of any similar benefits provided for in the Sirgo Employment Agreement), Dr. Sirgo has received or will receive the following benefits pursuant to the Sirgo Retirement Agreement: (i) a cash payment of $0.8 million (less applicable withholdings) which was paid in September 2017; and (ii) an additional cash payment equal to $0.8 million (less applicable withholdings) which was paid in January 2018. In addition, pursuant to the Sirgo Retirement Agreement: (i) as of the Sirgo Retirement Date, all previously vested options held by Sirgo to purchase shares of Common Stock will continue for the life of such options (as opposed to such options terminating on the 90 th (ii) Dr. Sirgo will be entitled to receive his ordinary year end equity bonus award (in the form of RSUs) for his service as an officer during 2017, as determined by the Compensation Committee of the Board (or the Sirgo 2017 Equity Award); provided, however, that (A) with respect to RSUs which by their terms would vest with the passage of time (or Time Vesting RSUs), Dr. Sirgo shall receive a number of shares of Common Stock equal to (1) the Net Present Value (as defined in the Sirgo Retirement Agreement) of the Time Vesting RSUs that would have been issued to Dr. Sirgo for the Sirgo 2017 Equity Award had he not retired divided by (2) the 30-day 30-day (iii) as of the Sirgo Retirement Date, all previously granted Time Vesting RSUs issued to Dr. Sirgo pursuant to the Plan that are unvested as of the Sirgo Retirement Date shall terminate and, in lieu thereof, Dr. Sirgo shall receive a one-time 30-day one-time (iv) Dr. Sirgo will continue to be entitled to receive (if applicable) one hundred percent (100%) of his regular award of vested Common Stock (or the LTIP Stock) under the LTIP, with the amount of such LTIP Stock to be determined and issued in accordance with the terms and provisions of the LTIP. The issuance of the LTIP Stock to Dr. Sirgo as provided for above shall occur, if applicable, concurrently with the issuance of LTIP Stock to the Company’s officers, but no later than March 15, 2018. Should Dr. Sirgo voluntarily resign from the Board, in each case prior to payment of any amount of LTIP Stock, Dr. Sirgo’s right to receive LTIP Stock from and after that time shall terminate. In the event a Change in Control (as defined in the Sirgo Retirement Agreement) occurs on or within twelve (12) months following the Retirement Date with a company with whom Dr. Sirgo had contact about a potential transaction in his capacity as an employee of the Company prior to the Sirgo Retirement Date, then the Company shall issue to Dr. Sirgo, as an additional retirement benefit, fully vested shares of Common Stock in an amount equal to the number of shares Dr. Sirgo would have received pursuant to the LTIP had he remained employed with us through the Change in Control. For purposes of the Sirgo Retirement Agreement, the term “Change of Control” means the occurrence of any one or more of the following events (it being agreed that, with respect to paragraphs (i) and (iii) of this definition below, a “Change of Control” shall not be deemed to have occurred if the applicable third party acquiring party is an “affiliate” of the Company within the meaning of Rule 405 promulgated under the Securities Act of 1933, as amended): (i) an acquisition (whether directly from the Company or otherwise) of any voting securities of the Company (or the Voting Securities) by any “Person” (as the term person is used for purposes of Section 13(d) or 14(d) of the Securities and Exchange Act of 1934, as amended (or the 1934 Act)), immediately after which such Person has “Beneficial Ownership” (within the meaning of Rule 13d-3 (ii) the individuals who, as of the date hereof, are members of the Company’s board of directors cease, by reason of a financing, merger, combination, acquisition, takeover or other non-ordinary fifty-one (iii) approval by the Company’s board of directors and, if required, the Company’s stockholders, or execution by us of any definitive agreement with respect to, or the consummation of (it being understood that the mere execution of a term sheet, memorandum of understanding or other non-binding (A) a merger, consolidation or reorganization involving the Company, where either or both of the events described in clauses (i) or (ii) above would be the result; (B) a liquidation or dissolution of or appointment of a receiver, rehabilitator, conservator or similar person for, or the filing by a third party of an involuntary bankruptcy against, the Company; or (C) an agreement for the sale or other disposition of all or substantially all of the assets of the Company to any Person (other than a transfer to a subsidiary of the Company).” The Sirgo Retirement Agreement also contains other customary provisions, including provisions for Dr. Sirgo’s continuing participation in certain company employee benefit plans, mutual releases of claims by the Company and Dr. Sirgo (subject to certain exceptions) and a covenant of cooperation. Vasisht retirement agreement On January 12, 2018, Niraj Vasisht, the Company’s former Senior Vice President and Chief Technology Officer, executed a Retirement Agreement (which is referred to as the Vasisht Retirement Agreement) memorializing the terms of Dr. Vasisht’s voluntary retirement from the Company, which was effective February 4, 2018 (which is referred to as the Vasisht Retirement Date, with the period from January 12, 2018, to the Vasisht Retirement Date being referred to herein as the Vasisht Transition Period). Pursuant to the Vasisht Retirement Agreement, Dr. Vasisht continued to serve as the Company’s Senior Vice President and Chief Technology Officer during the Vasisht Transition Period. By entering into the Vasisht Retirement Agreement, the Company and Dr. Vasisht agreed to terminate Vasisht’s employment agreement with the Company, dated October 8, 2008 (collectively with the related confidentiality agreement between the Company and Vasisht, the Vasisht Employment Agreement) as of the Vasisht Retirement Date, subject to those provisions of the Vasisht Employment Agreement which survive termination (as the same were modified by the Vasisht Retirement Agreement), including provisions related to confidentiality, non-solicitation non-competition. In connection with his retirement from the Company, and in consideration of his service to the Company (and in lieu of any similar benefits provided for in the Vasisht Employment Agreement), Dr. Vasisht received or will receive the following benefits pursuant to the Vasisht Retirement Agreement: (i) a cash separation payment of $0.33 million (less applicable withholdings), in two equal payments of $0.165 million each: the first payment paid January 19, 2018, the second payment to be paid on April 1, 2018; (ii) an additional cash payment equal to $0.02 million (less applicable withholdings) paid on January 19, 2018, in consideration for a previously deferred raise in Dr. Vasisht’s base salary; (iii) if a Change of Control (as defined in the Vasisht Employment Agreement) occurs before July 1, 2018, Dr. Vasisht will be entitled to the cash payments provided for in Paragraph 4(d) of the Vasisht Employment Agreement (namely, a cash payment equal to: (A) Dr. Vasisht’s annual base salary plus (iv) for a period of 12 months from the Vasisht Retirement Date, Dr. Vasisht will serve as a consultant to the Company as requested from time to time during such period with respect to the Company’s research and development operations at the rate of $200 per hour. In addition, pursuant to the Vasisht Retirement Agreement: (i) as of the Vasisht Retirement Date, all previously vested options held by Dr. Vasisht to purchase shares of Common Stock will continue for the life of such options (as opposed to such options terminating on the 90 th (ii) Vasisht will be entitled to receive his ordinary year end equity bonus award (in the form of RSUs) for his service as an officer of the Company during 2017, as determined by the Compensation Committee (or the Vasisht 2017 Equity Award); provided, however, that (A) with respect to Time Vesting RSUs, Dr. Vasisht shall receive a number of shares of Common Stock equal to (1) the Net Present Value (as defined in the Vasisht Retirement Agreement) of the Time Vesting RSUs that would have been issued to Dr. Vasisht for the Vasisht 2017 Equity Award had he not retired divided by (2) the 30-day (iii) Dr. Vasisht shall receive one hundred percent (100%) of his regular award of vested LTIP Stock under the LTIP, with the amount of such LTIP Stock to be determined and issued in accordance with the terms and provisions of the LTIP, in consideration for his work in 2017, and Dr. Vasisht shall also be considered for a bonus in consideration for his work in 2017 in accordance with the normal procedures and conditions for award of a bonus; and (iv) as of the Vasisht Retirement Date, all previously granted Time Vesting RSUs issued to Dr. Vasisht pursuant to the Plan that are unvested as of the Vasisht Retirement Date shall terminate and, in lieu thereof, Vasisht shall receive a one-time 30-day The Vasisht Retirement Agreement also contains other customary provisions, including provisions for Dr. Vasisht’s continuing participation in certain company benefit plans, mutual releases of claims by the Company and Dr. Vasisht (subject to certain exceptions) and a non-disparagement

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	18. Commitments and contingencies: Operating leases Since November 2007, the Company has leased space for their corporate offices. Lease expense for the corporate office was $0.3 million, $0.3 million and $0.3 million for each of the years ended December 31, 2017, 2016 and 2015, respectively. The Company leased new space for their corporate offices, which began March 2015 for 89 months. The future minimum commitment on the new operating lease at December 31, 2017 is as follows: Years ending December 31, 2018 $ 341 2019 351 2020 360 2021 370 2022 219 $ 1,641 Indemnifications The Company’s directors and officers are indemnified against costs and expenses related to stockholder and other claims (i.e., only actions taken in their capacity as officers and directors) that are not covered by the Company’s directors and officers insurance policy. This indemnification is ongoing and does not include a limit on the maximum potential future payments, nor are there any recourse provisions or collateral that may offset the cost. On February 5, 2018, the Company entered into indemnification agreements (the “Indemnification Agreements”) with each member of its board of directors (each, an “Indemnitee”). The form of Indemnification Agreement was approved by the board of directors. The Indemnification Agreements are intended to clarify and supplement the indemnification rights and obligations of the Indemnitees and Company already included in the Company’s Certificate of Incorporation, as amended, and Second Amended and Restated Bylaws, and generally provide that, subject to certain exceptions specified in the Indemnification Agreements, the Company will indemnify the Indemnitee to the fullest extent permitted by Delaware law in the event the Indemnitee becomes subject to or a participant in certain claims or proceedings as a result of the Indemnitee’s service as a director or officer. The Company will also, subject to certain exceptions and repayment conditions, be obligated to advance to the Indemnitee specified indemnifiable expenses incurred in connection with such claims or proceedings. No events have occurred as of the date of this report which would trigger any liability under the agreements. Post marketing requirements On October 5, 2017, the Company entered a subsequent party acknowledgement relating to its participation in the Opioid PMR Consortium (the “OPC”). The participants are member companies, collectively undertaking various observational and clinical studies to satisfy certain post-marketing requirements by the FDA as holders of a NDA for extended-release and long-acting opioid analgesics. As a requirement of joining the OPC, the Company was required to pay its share of the previous expenses incurred and funded by the existing member companies. The Company’s pro-rata $4.3 million, which was paid during the fourth quarter of 2017. Ongoing expenses will be shared equally by the member companies and paid monthly from 2018 through 2020. Certain rights of CDC IV The Company and CDC IV are parties to the CDLA pursuant to which CDC IV has previously provided funds to the Company for the development of the Company’s ONSOLIS ® mid-single ® In September 2007, in connection with CDC IV’s consent to the North American Meda transaction, the Company, among other transactions with CDC IV, granted CDC IV a 1% royalty on net sales of the next BEMA ® ® ® The Company records such royalties as costs of sales occur. In April 2016, CDC IV exercised its right pursuant to the Royalty Purchase and Amendment Agreement to exchange its royalty rights to the next BEMA ® ® ® ® Litigation related to ONSOLIS ® On November 2, 2010, Aquestive filed an action against the Company and its commercial partners for ONSOLIS ® ® ® ® ® ® ® The Company strongly refuted as without merit Aquestive’s assertion of patent infringement, which relates to the Company’s confidential, proprietary manufacturing process for ONSOLIS ® In November 2011, the USPTO rejected all 191 claims of Aquestive’s ’588 Patent. On January 20, 2012, the Company filed requests for reexamination before the USPTO of Aquestive’s ’891 Patent, and’292 Patent, the two additional patents asserted by Aquestive, demonstrating that all claims of those two patents were anticipated by or obvious in the light of prior art references, including prior art references not previously considered by the USPTO, and thus invalid. The USPTO granted the requests for reexamination with respect to Aquestive’s ’292 and ’891 Patents. In its initial office action in each, the USPTO rejected every claim in each patent. As expected, in the ’891 Patent and ’292 Patent Ex Parte Reexamination proceedings, Aquestive amended the claims several times and made multiple declarations and arguments in an attempt to overcome the rejections made by the USPTO. These amendments, declarations and other statements regarding the claim language significantly narrowed the scope of their claims in these two patents. In the case of the ’891 Patent, not one of the original claims survived reexamination and five separate amendments were filed confirming the Company’s position that the patent was invalid. Additionally, the Company believes that arguments and admissions made by Aquestive prevent it from seeking a broader construction during any subsequent litigation by employing arguments or taking positions that contradict those made during prosecution. A Reexamination Certificate for Aquestive’s ’891 Patent in its amended form was issued August 21, 2012 (the ’891C1 Patent). A Reexamination Certificate for Aquestive’s ’292 Patent in its amended form was issued on July 3, 2012 (t’292C1 Patent). These actions by the USPTO confirm the invalidity of the original patents and through the narrowing of the claims in the reissued patents strengthens the Company’s original assertion that its products and technologies do not infringe on Aquestive’s original patents. On June 12, 2013, despite the Company’s previously noted success in the prior ex parte reexaminations for the ’292 and ’891 Patents, the Company filed requests for inter partes reviews (“IPRs”) on the narrowed yet reexamined patents, the ’292 C1 and ’891 C1 Patents, to challenge their validity and continue to strengthen its position. On November 13, 2013, the USPTO decided not to institute the two IPRs for the ’891 C1 and ’292 C1 Patents. The USPTO’s decision was purely on statutory grounds and based on a technicality (in that the IPRs were not filed within what the UPSTO determined to be the statutory period) rather than substantive grounds. Thus, even though the IPRs were not instituted, the USPTO decision preserves the Company rights to raise the same arguments at a later time (e.g., during litigation). Regardless, the Company’s assertion that its products and technologies do not infringe the original ’292 and ’891 Patents and, now, the reexamined ’891 C1 and ’292 C1 Patents remains the same. Importantly, in the case of Aquestive’s ’588 Patent, after the reexamination proceedings (and its appeals process), on April 17, 2014, the PTAB issued a Decision on Appeal affirming the Examiner’s rejection (and confirming the invalidity) of all the claims of the ’588 Patent. Aquestive did not request a rehearing by the May 17, 2014 due date for making such a request and did not further appeal the Decision to the Federal Court of Appeals by the June 17, 2014 due date for making such an appeal. Subsequently, on August 5, 2014, the USPTO issued a Certificate of Reexamination cancelling the ‘588 Patent claims. Based on the Company’s original assertion that its proprietary manufacturing process for ONSOLIS ® ® ® ® ® ® Litigation related to BUNAVAIL ® RB and Aquestive On October 29, 2013, Reckitt Benckiser, Inc., RB Pharmaceuticals Limited, and Aquestive (collectively, the RB Plaintiffs) filed an action against the Company relating to its BUNAVAIL ® ® ® On May 21, 2014, the Court granted the Company’s motion to dismiss. In doing so, the Court dismissed the case in its entirety. The RB Plaintiffs did not appeal the Court Decision by the June 21, 2014 due date and therefore, the dismissal will stand and the RB Plaintiffs lose the ability to challenge the Court Decision in the future. The possibility exists, however, that the RB Plaintiffs could file another suit alleging infringement of the ‘832 Patent. If this occurs, based on the Company’s original position that its BUNAVAIL ® On September 20, 2014, based upon the Company’s position and belief that its BUNAVAIL ® ® 15-19. inter partes However, in issuing its November 5, 2014 decision not to institute the IPR, the PTAB construed the claims of the ‘378 Patent narrowly. As in prior litigation proceedings, the Company believes these IPR and the reexamination filings will provide support for maintaining the stay until the IPR and reexamination proceedings conclude. Indeed, given the PTAB’s narrow construction of the claims of the ‘378 Patent, the Company filed a motion to withdraw the ‘378 Patent from the case on December 12, 2014. In addition, the Company also filed a joint motion to continue the stay (with RB Plaintiffs) in the proceedings on the same day. Both the motion to withdraw the ‘378 Patent from the proceedings and motion to continue the stay were granted. On September 22, 2014, the RB Plaintiffs filed an action against the Company (and its commercial partner) relating to the Company’s BUNAVAIL ® ® ® In a related matter, on October 28, 2014, the Company filed multiple IPR requests on the ’167 Patent demonstrating that certain claims of such patent were anticipated by or obvious in light of prior art references, including prior art references not previously considered by the USPTO, and thus, invalid. The USPTO instituted three of the four IPR requests and we filed a request for rehearing for the non-instituted ® On January 22, 2014, Aquestive filed a Petition for IPR on US Patent No. 7,579,019 (the ‘019 Patent). The Petition asserted that the claims of the ‘019 Patent are alleged to be unpatentable over certain prior art references. The IPR was instituted on August 6, 2014. An oral hearing was held in April 2015 and a decision upholding all seven claims was issued August 5, 2015. In September 2015, Aquestive requested that the PTAB rehear the IPR. On December 19, 2016, the PTAB issued a final decision denying Aquestive’s request for rehearing. Aquestive did not file a notice of appeal to the Federal Circuit by February 20, 2017, and therefore, the PTAB’s decision upholding all claims of the Company’s ‘019 patent are final and unappealable. On January 13, 2017, Aquestive filed a complaint in the United States District Court for the District of New Jersey alleging BELBUCA ® Teva Pharmaceuticals (formerly Actavis) On February 8, 2016, the Company received a notice relating to a Paragraph IV certification from Teva Pharmaceuticals (“Teva”) (formerly Actavis Laboratories UT, Inc.) seeking to find invalid three Orange Book listed patents (the “Patents”) relating specifically to BUNAVAIL ® ® ® 30-month The Company has asserted three different patents against Teva, the ’019 patent, the ‘866 patent, and the ’177 patent. Teva did not raise non-infringement non-infringement The Company believes that Teva is unlikely to prevail on its claims that the ’019, ’866, and ’177 Patents are invalid, and, as the Company has done in the past, intends to vigorously defend its intellectual property. Each of the three patents carry the presumption of validity and, the ‘019 Patent has already been the subject of an unrelated IPR before the USPTO under which the Company, and all claims of the ‘019 Patent survived. Aquestive’s request for rehearing of the final IPR decision regarding the ‘019 Patent was denied by the USPTO on December 19, 2016. Aquestive did not file a timely appeal at the Federal Circuit. On December 20, 2016 the USPTO issued U.S. Patent No. 9,522,188 (“the ’188 patent”), and this patent was properly listed in the Orange Book as covering the BUNAVAIL ® On January 31, 2017, the Company received a notice relating to a Paragraph IV certification from Teva relating to Teva’s ANDA on additional strengths of BUNAVAIL ® ® 30-month ® On May 23, 2017, the USPTO issued U.S. Patent 9,655,843 (the “’843 Patent”), and this patent was properly listed in the Orange Book as covering the BUNAVAIL ® Finally, on October 12, 2017, the Company announced that it had entered into a settlement agreement with Teva that resolved the Company’s BUNAVAIL ® non-exclusive ® Litigation related to BELBUCA ® The Company received notices regarding Paragraph IV certifications from Teva on November 8, 2016, November 10, 2016, and December 22, 2016, seeking to find invalid two Orange Book listed patents (the “Patents”) relating specifically to BELBUCA ® ® ® 30-month The Company asserted two different patents against Teva, the ’019 Patent and the ’866 Patent. Teva did not contest infringement of the claims of the ’019 Patent and also did not contest infringement of the claims of the ’866 Patent that cover BELBUCA ® The Company believed that Teva was unlikely to prevail on its claims that the ’019 and ’866 Patents are invalid, and, as the Company has done in the past, vigorously defended its intellectual property. Both of the patents carry the presumption of validity, and the ’019 Patent has already been the subject of an unrelated IPR before the USPTO under which the Company prevailed, and all claims of the ‘019 Patent survived. Aquestive’s request for rehearing of the final IPR decision regarding the ’019 Patent was denied by the USPTO on December 19, 2016. Aquestive did not file a timely appeal at the Federal Circuit. On May 23, 2017, the USPTO issued U.S. Patent 9,655,843 (the “’843 Patent”), and this patent was properly listed in the Orange Book as covering the BELBUCA ® On August 28, 2017, the Court entered orders staying both BELBUCA ® ® ® Finally, on February 6, 2018, the Company announced that it had entered into a settlement agreement with Teva that resolved the Company’s BELBUCA ® non-exclusive ® patents-in-suit ® ®

Selected Quarterly Results (Una

Selected Quarterly Results (Unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Results (Unaudited)	SELECTED QUARTERLY RESULTS (UNAUDITED) The following table sets forth certain quarterly financial data for the periods indicated (in thousands, except per share data): Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 29,478 $ 8,744 $ 11,253 $ 12,510 Gross profit 23,833 4,573 6,808 7,275 Income (loss) from operations 7,903 (12,987 ) (10,045 ) (14,291 ) Net income (loss) 48,325 (14,879 ) (11,951 ) (16,210 ) Basic income (loss) per share 0.89 (0.27 ) (0.21 ) (0.31 ) Diluted income (loss) per share 0.87 (0.27 ) (0.21 ) (0.30 ) Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 3,040 $ 5,004 $ 3,571 $ 3,931 Gross profit 490 910 1,257 1,631 Loss from operations (17,942 ) (15,594 ) (15,199 ) (15,200 ) Net loss (18,733 ) (16,486 ) (15,977 ) (15,942 ) Basic loss per share (0.35 ) (0.31 ) (0.30 ) (0.29 ) Diluted loss per share (0.35 ) (0.31 ) (0.30 ) (0.29 ) Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 13,054 $ 1,733 $ 1,235 $ 32,209 Gross profit 11,930 (888 ) (464 ) 29,552 Income (loss) from operations (7,800 ) (18,681 ) (19,652 ) 10,954 Net (loss) income (8,193 ) (19,211 ) (20,439 ) 10,171 Basic (loss) income per share (0.16 ) (0.37 ) (0.39 ) 0.20 Diluted (loss) income per share (0.16 ) (0.37 ) (0.39 ) 0.20

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts and Reserves	12 Months Ended
	Dec. 31, 2017
Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts and Reserves	BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS AND RESERVES Balance at Charged Charged to Deductions Balance at (In thousands) Description Valuation allowance for deferred tax assets Year ended December 31, 2017: $ 109,030 $ (37,515 ) $ — $ — $ 71,515 Year ended December 31, 2016: $ 84,960 $ 24,070 $ — $ — $ 109,030 Year ended December 31, 2015: $ 72,061 $ 12,899 $ — $ — $ 84,960 Allowance for rebates Year ended December 31, 2017: $ 3,842 $ 17,236 $ (132 ) $ (15,298 ) $ 5,648 Year ended December 31, 2016: $ 4,470 $ (1,204 ) $ 11,501 $ (10,925 ) $ 3,842 Year ended December 31, 2015: $ 939 $ 2,118 $ 6,360 $ (4,947 ) $ 4,470 Allowance for price adjustments and chargebacks Year ended December 31, 2017: $ 602 $ 6,738 $ (3 ) $ (3,412 ) $ 3,925 Year ended December 31, 2016: $ 383 $ 36 $ 1,711 $ (1,528 ) $ 602 Year ended December 31, 2015: $ 400 $ (2,118 ) $ 3,259 $ (1,158 ) $ 383 Allowance for inventory obsolescence Year ended December 31, 2017: $ — $ 243 $ — $ — $ 243 Year ended December 31, 2016: $ — $ — $ — $ — $ — Year ended December 31, 2015: $ — $ 213 $ (213 ) $ — $ —

Nature of Business and Summar27

Nature of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Organization	Organization BioDelivery Sciences International, Inc. and subsidiaries (the “Company”) was incorporated in the State of Indiana on January 6, 1997 and reincorporated as a Delaware corporation in 2002. The Company’s subsidiaries are Arius Pharmaceuticals, Inc., a Delaware corporation (“Arius One”) and Arius Two, Inc., a Delaware corporation (“Arius Two”), each of which are wholly-owned, and its majority-owned subsidiary, Bioral Nutrient Delivery, LLC, a Delaware limited liability company (“BND”). The Company is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. The Company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA ® As used herein, the Company’s common stock, par value $.001 per share, is referred to as the “Common Stock”.
Principles of consolidation	Principles of consolidation The consolidated financial statements include the accounts of the Company, Arius One, Arius Two and BND. For each period presented BND has been an inactive subsidiary. All significant inter-company balances and transactions have been eliminated.
Use of estimates in financial statements	Use of estimates in financial statements The preparation of the accompanying consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company reviews all significant estimates affecting the consolidated financial statements on a recurring basis and records the effect of any necessary adjustments prior to their issuance. Significant estimates of the Company include: revenue recognition, sales allowances such as returns of product sold, government program rebates, customer coupon redemptions, wholesaler/pharmacy discounts, product service fees, rebates and chargebacks, sales bonuses, stock-based compensation, determination of fair values of assets and liabilities relating to business combinations, and deferred income taxes.
Reacquisition of BELBUCA	Reacquisition of BELBUCA ® On December 7, 2016, the Company entered into an agreement (the “Termination Agreement”) with Endo Pharmaceuticals, Inc. (“Endo”) terminating Endo’s licensing of rights to the Company’s BELBUCA ® ® ® ®
Reclassification	Reclassification Certain amounts were reclassified between Accounts Receivable and Accounts Payable and Accrued Expenses for the year ended December 31, 2016 Consolidated Balance Sheet and in the Consolidated Statement of Cash Flows for the years ended December 31, 2016 and 2015 to conform to current year presentation to reflect the right of offset and practice of settling certain liabilities with our wholesale customers. Certain amounts were also reclassified between Accounts Payable and Accrued Liabilities in note 3, for the year ended December 31, 2016 to conform to current year presentation. The Company also reclassified certain amounts between Machinery & Equipment and Idle Equipment in note 4, for the year ended December 31, 2016. These reclassifications had no effect on the previously reported net cash flows from operations, activities or net losses.
Certain risks, concentrations and uncertainties	Certain risks, concentrations and uncertainties The Company relies on certain materials used in its development and third-party manufacturing processes, most of which are procured from three contract manufacturers and two active pharmaceutical ingredient (“API”) suppliers for BELBUCA ® ® ® ® In addition, the Company utilizes only two contract manufacturers to create the BELBUCA ® ® ® ® Key components used in the manufacture of ONSOLIS ® The Company sells its BELBUCA ® ® December 31, Customers 2017 2016 Customer A 47 % 36 % Customer B 22 % 28 % Customer C 26 % 28 % Total 95 % 92 % These three customers accounted for 92%, 91% and 90% of total annual sales during the years ended December 31, 2017, 2016 and 2015 respectively.
Cash	Cash The Company places cash on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation covers $0.25 million for substantially all depository accounts. As of December 31, 2017, the Company had approximately $21.2 million, which exceeded these insured limits. As of December 31, 2016, the Company had approximately $32.0 million, which exceeded these insured limits.
Accounts receivable	Accounts receivable The Company typically requires its customers to remit payments within the first 30 to 37 days, depending on the customer and the products purchased. In addition, the Company offers wholesale distributors a prompt payment discount if they make payments within these deadlines. This discount is generally 2% but may be higher in some instances due to product launches or customer and/or industry expectations. Because the Company’s wholesale distributors typically take the prompt payment discount, the Company accrues 100% of the prompt payment discounts, based on the gross amount of each invoice, at the time of sale, and the Company applies earned discounts at the time of payment. The allowance for prompt payment discounts was $0.2 million and $0.05 million as of December 31, 2017 and 2016, respectively. The Company performs ongoing credit evaluations and does not require collateral. As appropriate, the Company establishes provisions for potential credit losses. As such, there were no allowances for doubtful accounts as of December 31, 2017 or 2016. The Company writes off accounts receivable when management determines they are uncollectible and credits payments subsequently received on such receivables to bad debt expense in the period received. Write-offs during the years ending December 31, 2017, 2016 and 2015 were $0, $0.02 million and $0, respectively.
Inventory	Inventory Inventories are stated at the lower of cost or net realizable value with costs determined for each batch under the first-in, first-out On a quarterly basis, the Company analyzes its inventory levels and records allowances for inventory that has become obsolete, inventory that has a cost basis more than the expected net realizable value and inventory that is more than expected demand based upon projected product sales. The Company recorded $0.2 million in inventory obsolescence as of December 31, 2017. There were no allowances recorded as of December 31, 2016. Inventory is composed of the following at December 31: 2017 2016 Raw Materials & Supplies $ 1,338 $ 978 Work-in-process 3,135 1,660 Finished Goods 1,861 730 Finished Goods Reserve (243 ) — Total Inventories $ 6,091 $ 3,368
Property and equipment	Property and equipment The Company records property and equipment at cost less accumulated depreciation, which is computed on a straight-line basis over its estimated useful lives, generally 3 to 10 years. The Company evaluates the carrying value of the idle equipment when events or changes in circumstances indicate the related carrying amount may not be recoverable. During the year ended December 31, 2017, $0.7 million of idle equipment was placed back into production to support manufacturing of BELBUCA ® ® re-tooled, ®
Intangibles and goodwill	Intangibles and goodwill The Company reviews intangible assets with finite lives (“other intangible assets”) for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company uses an estimate of the undiscounted cash flows over the remaining life of its other intangible assets, or related group of assets where applicable, in measuring whether the assets to be held and used will be realizable. In the event of impairment, the Company would discount the future cash flows using its then estimated incremental borrowing rate to estimate the amount of the impairment. There were no impairment charges recognized on finite lived intangibles in 2017, 2016 or 2015. Intangible assets with finite useful lives are amortized over the estimated useful lives as follows: Estimated Licenses 15 years BELBUCA ® 10 years U.S. product rights 8-12 years EU product rights 7-11 Goodwill is evaluated for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying amount may not be recoverable. During the evaluation of the potential impairment of goodwill, either a qualitative or a quantitative assessment may be performed. If a qualitative evaluation determines that it is more likely than not that no impairment exists, then no further analysis is performed. If a qualitative evaluation is unable to determine whether it is more likely than not that impairment has occurred, a quantitative evaluation is performed. If the carrying value exceeds the fair value, an impairment charge is recorded based on that difference. There were no goodwill impairment charges in 2017, 2016 or 2015.
Deferred revenue	Deferred revenue Consistent with the Company’s revenue recognition policy, deferred revenue represents cash received in advance for licensing fees, consulting, research and development services and related supply agreements. Such payments are reflected as deferred revenue until recognized under the Company’s revenue recognition policy. Deferred revenue is classified as current if management believes the Company will be able to recognize the deferred amount as revenue within twelve months of the balance sheet date. Deferred revenue is recognized when the product is sold to the end user, based upon prescriptions filled. To estimate product sold to end users, the Company relies on third-party information, including prescription data and information obtained from significant distributors with respect to their inventory levels and sales to customers. Deferred revenue is recorded net of estimated allowances for rebates, price adjustments, chargebacks, prompt payment and other discounts. Estimated allowances are recorded and classified as accrued expenses in the accompanying balance sheets as of December 31, 2017 and 2016 (see note 3). The Company deferred sales, until January 1, 2017, of BUNAVAIL ® ®
Revenue recognition	Revenue recognition Net product sales Beginning in the first quarter of 2017, the Company had determined that it had sufficient experience with BELBUCA ® ® ex-factory ® ® can reasonably estimate the amount of future product returns, and therefore, the risk of estimating product returns has been substantially eliminated. The effect in income from operations and on net income is that the Company can recognize revenue earlier on the sell-in The Company establishes allowances for estimated rebates, chargebacks and product returns based on numerous qualitative and quantitative factors, including: • the number of and specific contractual terms of agreements with customers; • estimated levels of inventory in the distribution channel; • historical rebates, chargebacks and returns of products; • direct communication with customers; • anticipated introduction of competitive products or generics; • anticipated pricing strategy changes by the Company and/or its competitors; • analysis of prescription data gathered by a third-party prescription data provider; • the impact of changes in state and federal regulations; and • the estimated remaining shelf life of products. In its analyses, the Company uses prescription data purchased from a third-party data provider to develop estimates of historical inventory channel sell-through. The Company utilizes an internal analysis to compare historical net product shipments to estimated historical prescriptions written. Based on that analysis, management develops an estimate of the quantity of product in the channel which may be subject to various rebate, chargeback and product return exposures. To estimate months of ending inventory in the Company’s distribution channel, the Company divides estimated ending inventory in the distribution channel by the Company’s recent prescription data, not considering any future anticipated demand growth beyond the succeeding quarter. Monthly for each product line, the Company prepares an internal estimate of ending inventory units in the distribution channel by adding estimated inventory in the channel at the beginning of the period, plus net product shipments for the period, less estimated prescriptions written for the period. This is done for each product line by applying a rate of historical activity for rebates, chargebacks and product returns, adjusted for relevant quantitative and qualitative factors discussed above, to the potential exposed product estimated to be in the distribution channel. Product returns 18-month Rebates Price adjustments and chargebacks The Company, from time to time, offers certain promotional product-related incentives to its customers. These programs include certain product incentives to pharmacy customers and other sales stocking allowances. The Company has voucher programs for BELBUCA ® ® point-of-sale Prompt payment discounts Gross to net accruals License and development agreements The Company periodically enters into license and development agreements to develop and commercialize its products. The arrangements typically are multi-deliverable arrangements that are funded through upfront payments, milestone payments and other forms of payment. The Company currently has multiple license and development agreements that are described in notes 6, 8 and 9. Depending on the nature of the contract these revenues are classified as research and development reimbursements or contract revenue.
Deferred cost of sales	Deferred cost of sales Prior to January 1, 2017, the Company deferred its cost of sales relating to BUNAVAIL ® ex-factory ® ® The Company incurred $1.7 million of deferred costs of sales for the year ended December 31, 2016, which is included in other current assets in the accompanying balance sheets. There was no deferred cost of sales for the year ended December 31, 2017.
Cost of sales	Cost of sales Cost of sales includes the direct costs attributable to the production of BELBUCA ® ® ® ® For BREAKYL ™ ™ out-licensed
Research and development expenses	Research and development expenses Research and development expenses consist of product development expenses incurred in identifying, developing and testing product candidates. Product development expenses consist primarily of labor, benefits and related employee expenses for personnel directly involved in product development activities; fees paid to professional service providers for monitoring and analyzing clinical trials; expenses incurred under joint development agreements; regulatory costs; costs of contract research and manufacturing of inventory used in testing and clinical trials; and the cost of facilities used by the Company’s product development personnel. Product development expenses are expensed as incurred and reflect costs directly attributable to product candidates in development during the applicable period and to product candidates for which the Company has discontinued development. Additionally, product development expenses include the cost of qualifying new current Good Manufacturing Practice (“cGMP”) third-party manufacturers for the Company’s product candidates, including expenses associated with any related technology transfer. All indirect costs (such as salaries, benefits or other costs related to the Company’s accounting, legal, human resources, purchasing, information technology and other general corporate functions) associated with individual product candidates are included in general and administrative expenses. Research and development expenses were $13.0 million, $18.9 million and $20.6 million for the years ended December 31, 2017, 2016 and 2016 respectively.
Advertising	Advertising Advertising costs, which include promotional expenses and the cost of placebo samples, are expensed as incurred. Advertising expenses were $3.8 million, $4.2 million and $4.9 million for the years ended December 31, 2017, 2016 and 2015, respectively, and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations.
Shipping and handling costs	Shipping and handling costs Shipping and handling costs, which include expenses from our wholesalers, are expensed as incurred. Shipping and handling costs were $0.2 million, $0.05 and $0.05 million for the years ended December 31, 2017, 2016 and 2015, respectively, and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations.
Stock-based compensation	Stock-based compensation The Company has a stock-based compensation plan under which various types of equity-based awards are granted, including stock options, restricted stock units (RSUs) and performance-based RSUs. The fair value of stock option and RSUs, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. Forfeitures are recognized as they occur. The fair values of performance-based RSUs are recognized as compensation expense from the grant date to the end of the performance period. The Company uses the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (warrants and options). The grant date fair value of an RSU equals the closing price of our common stock on the trading day preceding the grant date. The fair value of each option and warrant is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on historical volatility of the Company’s Common Stock and other factors estimated over the expected term of the options. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield. In applying the Black-Scholes options-pricing model, assumptions are as follows: 2017 2016 2015 Expected price volatility 68.76%-78.79% 62.65%-80.78% 73.00%-76.78% Risk-free interest rate 1.77%-2.05% 0.56%-1.70% 1.25%-1.68% Weighted average expected life in years 6 years 6 years 6 years Dividend yield — — — The Company estimated fair values of derivative financial instruments using the Black-Scholes option valuation technique because it embodied all of the requisite assumptions (including trading volatility, estimated terms and risk-free rates) necessary to fairly value these instruments. In addition, option-based techniques were highly volatile and sensitive to changes in the Company’s trading market price which was high-historical volatility. Since derivative financial instruments were initially and subsequently carried at fair values, the Company’s operating results reflected the volatility in these estimates and assumption changes.
Recent accounting pronouncements	Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2014-09, 2015-14, 2014-09 2014-09 The Company used the modified retrospective approach upon adoption of this guidance effective January 1, 2018 using a cumulative effect adjustment to accumulated deficit. The Company utilized a comprehensive approach to assess the impact of the guidance on its contract portfolio. The Company reviewed its current accounting policies and practices to identify potential differences resulting from the application of the new requirements to its revenue contracts, including evaluation of performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price, allocating the transaction price to each separate performance obligation and accounting treatment of costs to obtain and fulfill contracts. In addition, the Company will update certain disclosures, as applicable, included in our financial statements to meet the requirements of the new guidance beginning in January 1, 2018. Under the new guidance, the Company is required to evaluate the impact of estimating variable consideration related to our product sales and licensing contracts. The Company will use the expected value method to estimate the total revenue of the contract, constrained by the probability that there would not be a significant revenue reversal in a future period. The Company will continue to evaluate the expected value of revenue over the term of the contract and adjust revenue recognition as appropriate. Based on this evaluation, the adoption will not have a material impact on the Company’s financial position, results of operations, cash flows, accounting policies, business processes, internal controls or disclosures. The FASB’s new leases standard, ASU 2016-02 2016-02 right-of-use In January 2017, the FASB issued ASU 2017-01, Business In January 2017, the FASB issued ASU Update No. 2017-04, Intangibles—Goodwill in-process 2017-04

Nature of Business and Summar28

Nature of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Company's Customers Accounts Receivable	The following table lists the Company’s customers that individually comprise greater than 10% of total accounts receivable: December 31, Customers 2017 2016 Customer A 47 % 36 % Customer B 22 % 28 % Customer C 26 % 28 % Total 95 % 92 %
Summary of Inventories	Inventory is composed of the following at December 31: 2017 2016 Raw Materials & Supplies $ 1,338 $ 978 Work-in-process 3,135 1,660 Finished Goods 1,861 730 Finished Goods Reserve (243 ) — Total Inventories $ 6,091 $ 3,368
Intangible Assets with Finite Useful Lives, Amortized Over Estimated Useful Lives	Intangible assets with finite useful lives are amortized over the estimated useful lives as follows: Estimated Licenses 15 years BELBUCA ® 10 years U.S. product rights 8-12 years EU product rights 7-11
Black Scholes Options-Pricing Model, Assumptions	In applying the Black-Scholes options-pricing model, assumptions are as follows: 2017 2016 2015 Expected price volatility 68.76%-78.79% 62.65%-80.78% 73.00%-76.78% Risk-free interest rate 1.77%-2.05% 0.56%-1.70% 1.25%-1.68% Weighted average expected life in years 6 years 6 years 6 years Dividend yield — — —

Accounts Payable and Accrued 29

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Summary of Components of Accounts Payable and Accrued Liabilities	The following table represents the components of accounts payable and accrued liabilities as of December 31: 2017 2016 Accounts payable $ 12,236 $ 9,397 Accrued rebates 5,648 3,842 Accrued compensation and benefits 3,472 2,052 Accrued acquisition costs 2,311 — Accrued returns 915 — Accrued royalties 488 518 Accrued clinical trial costs 234 615 Accrued legal 216 490 Accrued manufacturing costs — 200 Accrued sales and marketing costs — 193 Accrued other 629 265 Total accounts payable and accrued expenses $ 26,149 $ 17,572

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Summarized Category of Fixed Assets	Property and equipment, summarized by major category, consist of the following as of December 31: 2017 2016 Machinery & equipment $ 5,428 $ 4,476 Computer equipment & software 399 464 Office furniture & equipment 169 202 Leasehold improvements 44 53 Idle equipment 766 1,486 Total 6,806 6,681 Less accumulated depreciation (3,028 ) (2,451 ) Total property, plant & equipment, net $ 3,778 $ 4,230

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Text Block [Abstract]
Summary of Other Intangible Assets Net Consisting of Product Rights and Licenses	Other intangible assets, net, consisting of product rights and licenses are summarized as follows: December 31, 2017 Gross Carrying Accumulated Intangible Assets, Weighted average Product rights $ 6,050 $ (4,881 ) $ 1,169 1.21 BELBUCA ® 45,000 (4,500 ) 40,500 8.50 Licenses 1,900 (1,709 ) 191 0.54 Total intangible assets $ 52,950 $ (11,090 ) $ 41,860 10.25 December 31, 2016 Gross Carrying Accumulated Intangible Assets, Weighted average Product rights $ 9,050 $ (7,052 ) $ 1,998 9.11 Licenses 1,900 (1,613 ) 287 1.84 Total intangible assets $ 10,950 $ (8,665 ) $ 2,285 10.95
Schedule Estimated Aggregate Future Amortization Expenses for Other Intangible Assets	Estimated aggregate future amortization expenses for other intangible assets for each of the next five years and thereafter are as follows: Years ending December 31, 2018 $ 5,157 2019 5,157 2020 4,547 2021 4,500 2022 4,500 Thereafter 17,999 $ 41,860

Business Combination and BELB32

Business Combination and BELBUCA Acquisition (Tables) - BELBUCA [Member]	12 Months Ended
	Dec. 31, 2017
Summary of Asset Purchase Price and Estimated Values of Assets Acquired and Liabilities Assumed	The following table summarizes the consideration paid to acquire BELBUCA ® Asset purchase price: Deferred cash consideration to Endo $ 7,536 Total asset purchase price $ 7,536 Estimated fair value of assets acquired: Current BELBUCA ® work-in $ 5,412 BELBUCA ® 432 License and distribution rights intangible assets 45,000 Deferred tax liability (15,972 ) Amount attributable to assets acquired $ 34,872 Bargain purchase gain $ (27,336 )
Summary of Proforma Impact of Acquisition	The following pro forma combined results of operations are provided for the year ended December 31, 2016, as though the BELBUCA ® ® ® (in thousands, except per share data) December 31, Revenue $ 25,010 Net loss $ (201,769 ) Pro forma net loss per common share Basic $ (3.76 ) Diluted $ (3.76 )

Term Loan Agreement (CRG) (Tabl

Term Loan Agreement (CRG) (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Future Maturities of CRG Obligation	The following table represents future maturities of the CRG obligation as of December 31, 2017: 2018 $ — 2019 — 2020 20,054 2021 20,054 2022 20,054 Total maturities $ 60,162 Unamortized discount and loan costs (12,502 ) Total CRG obligation $ 47,660

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Summary of Net Sales by Product	The following table presents net sales by product for each of the years ended December 31 (in thousands): Year ended December 31, 2017 2016 2015 BELBUCA ® $ 26,980 $ — $ — BUNAVAIL ® 7,942 8,266 4,157 Net product sales $ 34,922 $ 8,266 $ 4,157

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Reconciliation of Federal Statutory Income Tax Rate	Reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows: 2017 2016 2015 Federal statutory income (benefit) tax rate (34.00 %) 34.00 % 34.00 % 2017 Tax Act, net deferred tax remeasurement (626.73 ) — — State taxes, net of federal benefit (2.01 ) 2.88 3.45 Stock compensation (5.18 ) (0.61 ) — Permanent differences-other (13.39 ) (1.00 ) (4.66 ) North Carolina tax rate change (32.75 ) — — Research and development (“R&D”) credit 5.54 0.98 0.95 Valuation release for bargain purchase gain (302.23 ) — — Other (1.36 ) (0.47 ) 0.64 Decrease (increase) in valuation allowance 709.88 (35.78 ) (34.38 ) (302.23 %) 0.00 % 0.00 %
Significant Components of Deferred Tax Assets and Liabilities	The tax effects of temporary differences and net operating losses that give rise to significant components of deferred tax assets and liabilities consist of the following: December 31, Deferred tax assets (liabilities) 2017 2016 Deferred revenue $ — $ 7,377 Basis difference in equipment (587 ) (1,084 ) Basis difference in intangibles (8,288 ) 1,201 Accrued liabilities and other 654 550 R&D credit 11,882 11,589 AMT credit 79 79 Stock options 6,115 5,697 Net operating loss carry-forward 61,660 83,621 71,515 109,030 Less: valuation allowance (71,515 ) (109,030 ) $ — $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Summary of Restricted Stock Activity	Restricted stock activity during the year ended December 31, 2017 was as follows: Number of Weighted Outstanding at January 1, 2017 4,584,297 $ 7.29 Granted: Executive officers 1,640,000 1.85 Directors 162,315 2.80 Employees 555,000 2.10 Vested (1,568,042 ) 2.17 Forfeitures (666,675 ) 2.71 Outstanding at December 31, 2017 4,706,895 $ 5.20
Summary of Stock Option Activity	Stock option activity for the years ended December 31, 2017, 2016 and 2015 is as follows: Number of Weighted Average Aggregate Outstanding at January 1, 2015 3,196,100 $ 4.32 $ 22,881 Granted in 2015: Others 684,629 8.14 Exercised (235,480 ) 3.52 Forfeitures (247,720 ) 12.65 Outstanding at December 31, 2015 3,397,529 $ 5.42 $ 3,124 Granted in 2016: Officers and Directors 95,000 $ 2.34 Others 558,373 3.12 Exercised (147,425 ) 2.01 Forfeitures (434,486 ) 13.17 Outstanding at December 31, 2016 3,468,991 $ 4.14 $ 0 Granted in 2017: Officers and Directors 83,658 $ 2.64 Others 873,017 1.96 Exercised (202,519 ) 2.17 Forfeitures (1,510,193 ) 5.13 Outstanding at December 31, 2017 2,712,954 $ 2.98 $ 1,190
Summary of Stock Options Outstanding	Options outstanding at December 31, 2017 are as follows: Range of Exercise Prices Number Weighted Average Weighted Average Aggregate $1.00 – 5.00 2,192,695 5.53 $ 2.72 $5.01 – 10.00 430,149 5.38 $ 6.29 $10.01 – 15.00 48,358 7.14 $ 13.13 $15.01 – 20.00 41,500 6.75 $ 16.27 2,712,954 $ 1,190
Summary of Stock Options Exercisable	Options exercisable at December 31, 2017 are as follows: Range of Exercise Prices Number Weighted Average Weighted Average Aggregate $1.00 – 5.00 1,400,022 3.48 $ 3.04 $5.01 – 10.00 345,257 5.43 $ 6.28 $10.01 – 15.00 35,439 7.13 $ 13.15 $15.01 – 20.00 41,500 6.75 $ 16.27 1,822,218 $ 561
Summary of Non-Vested Stock Options	Nonvested stock options as of December 31, 2017, and changes during the year then ended, are as follows: Nonvested Shares Shares Weighted Average Intrinsic Nonvested at January 1, 2017 829,431 Granted 960,175 Vested (363,701 ) Forfeited (540,421 ) Nonvested at December 31, 2017 885,484 $ 2.70 $ 629
Summary of Allocated Stock-based Compensation Expense	The Company’s stock-based compensation expense is allocated between research and development and selling, general and administrative as follows as of December 31: Stock-based compensation expense 2017 2016 2015 Research and Development $ 1.6 $ 2.5 $ 4.2 Selling, General and Administrative $ 13.2 $ 12.4 $ 10.0

Earnings per Common Share (Tabl

Earnings per Common Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Reconciliation of Numerators and Denominators of Basic and Diluted Earnings Per Common Share Computations	The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per common share computations for the years ended December 31, 2017, 2016 and 2015. December 31, 2017 2016 2015 Basic: Net income (loss) attributable to common stockholders $ 5,285 $ (67,138 ) $ (37,672 ) Weighted average common shares outstanding 55,355,802 53,679,134 52,384,876 Basic earnings (loss) per common share $ 0.10 $ (1.25 ) $ (0.72 ) Diluted: Effect of dilutive securities: Net income (loss) attributable to common stockholders 5,285 (67,138 ) (37,672 ) Adjustment to income for dilutive options and warrants — — — 5,285 (67,138 ) (37,672 ) Weighted average common shares outstanding 55,355,802 53,679,134 52,384,876 Effect of dilutive options and warrants 1,046,677 — — Diluted weighted average common shares outstanding 56,402,479 53,679,134 52,384,876 Diluted earnings (loss) per common share $ 0.09 $ (1.25 ) $ (0.72 )
Schedule of Total Outstanding Options, RSUs and Warrants	The following is the total outstanding options, RSUs and warrants for the years ended December 31, 2017, 2016 and 2015, respectively. 2017 2016 2015 Options, RSUs, warrants and convertible preferred stock to purchase Common Stock 9,555,869 10,228,929 9,788,838

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Commitment on the Remaining Operating Lease	The future minimum commitment on the new operating lease at December 31, 2017 is as follows: Years ending December 31, 2018 $ 341 2019 351 2020 360 2021 370 2022 219 $ 1,641

Selected Quarterly Results (U39

Selected Quarterly Results (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Results	The following table sets forth certain quarterly financial data for the periods indicated (in thousands, except per share data): Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 29,478 $ 8,744 $ 11,253 $ 12,510 Gross profit 23,833 4,573 6,808 7,275 Income (loss) from operations 7,903 (12,987 ) (10,045 ) (14,291 ) Net income (loss) 48,325 (14,879 ) (11,951 ) (16,210 ) Basic income (loss) per share 0.89 (0.27 ) (0.21 ) (0.31 ) Diluted income (loss) per share 0.87 (0.27 ) (0.21 ) (0.30 ) Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 3,040 $ 5,004 $ 3,571 $ 3,931 Gross profit 490 910 1,257 1,631 Loss from operations (17,942 ) (15,594 ) (15,199 ) (15,200 ) Net loss (18,733 ) (16,486 ) (15,977 ) (15,942 ) Basic loss per share (0.35 ) (0.31 ) (0.30 ) (0.29 ) Diluted loss per share (0.35 ) (0.31 ) (0.30 ) (0.29 ) Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 13,054 $ 1,733 $ 1,235 $ 32,209 Gross profit 11,930 (888 ) (464 ) 29,552 Income (loss) from operations (7,800 ) (18,681 ) (19,652 ) 10,954 Net (loss) income (8,193 ) (19,211 ) (20,439 ) 10,171 Basic (loss) income per share (0.16 ) (0.37 ) (0.39 ) 0.20 Diluted (loss) income per share (0.16 ) (0.37 ) (0.39 ) 0.20

Nature of Business and Summar40

Nature of Business and Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017USD ($)ManufacturerCustomer$ / shares	Dec. 31, 2016USD ($)$ / shares	Dec. 31, 2015USD ($)
Basis Of Presentation [Line Items]
Common Stock, par value | $ / shares	$ 0.001	$ 0.001
Number of contract manufacturers | Manufacturer	3
Percentage of amount due to vendors payable	22.80%	5.60%
Number of customers | Customer	3
FDIC insurance coverage	$ 250,000
Net deposit amount exceeding specified amount under FDIC	$ 21,200,000	$ 32,000,000
Discount for prompt payment	2.00%
Percentage of prompt payment discount, accrued	100.00%
Allowance for prompt payment of discount	$ 200,000	50,000
Allowance for Doubtful Accounts Receivable	0	0
Allowance for Doubtful Accounts Receivable, Write-offs	0	20,000	$ 0
Inventory obsolescence recorded	243,000	0
Impairment charges recognized on finite lived intangibles assets	0	0	0
Goodwill impairment charges	0	0	0
Product sales	34,922,000	8,266,000	4,157,000
Deferred revenue related to sales	$ 0	1,700,000
Sales return maximum duration	18 months
Offered period for sales return prior to expiration	6 months
Offered period for sales return subsequent to expiration	12 months
Discount for prompt payment	2.00%
Research and development expenses	$ 13,040,000	18,878,000	20,624,000
Advertising expenses	3,800,000	4,200,000	4,900,000
Shipping and handling costs	$ 200,000	$ 50,000	$ 50,000
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Basis Of Presentation [Line Items]
Total annual sales percentage	92.00%	91.00%	90.00%
BUNAVAIL [Member]
Basis Of Presentation [Line Items]
Idle equipment net		$ 3,700,000
Impairment loss	$ 0	0
Product sales	7,942,000	8,266,000	$ 4,157,000
Deferred cost of sales	$ 0	1,700,000
BELBUCA [Member]
Basis Of Presentation [Line Items]
Estimated useful lives of equipment	7 years
Idle equipment net	$ 700,000
Product sales	$ 26,980,000	$ 0
Endo Agreement [Member]
Basis Of Presentation [Line Items]
Termination agreement date	Dec. 7, 2016
License termination effective date	Jan. 6, 2017
Minimum [Member]
Basis Of Presentation [Line Items]
Period of payments from customers	30 days
Estimated useful lives of equipment	3 years
Accrual to payment cycle period	1 month
Maximum [Member]
Basis Of Presentation [Line Items]
Period of payments from customers	37 days
Estimated useful lives of equipment	10 years
Accrual to payment cycle period	3 months

Nature of Business and Summar41

Nature of Business and Summary of Significant Accounting Policies - Summary of Company's Customers Accounts Receivable (Detail) - Customer Concentration Risk [Member] - Accounts Receivable [Member]	Dec. 31, 2017	Dec. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivable	95.00%	92.00%
Customer A [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivable	47.00%	36.00%
Customer B [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivable	22.00%	28.00%
Customer C [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Accounts Receivable	26.00%	28.00%

Nature of Business and Summar42

Nature of Business and Summary of Significant Accounting Policies - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw Materials & Supplies	$ 1,338	$ 978
Work-in-process	3,135	1,660
Finished Goods	1,861	730
Finished Goods Reserve	(243)
Total Inventories	$ 6,091	$ 3,368

Nature of Business and Summar43

Nature of Business and Summary of Significant Accounting Policies - Intangible Assets with Finite Useful Lives, Amortized Over Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2017
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	15 years
BELBUCA License and Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	10 years
U.S. Product Rights [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	8 years
U.S. Product Rights [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	12 years
Eu Product Rights [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	7 years
Eu Product Rights [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	11 years

Nature of Business and Summar44

Nature of Business and Summary of Significant Accounting Policies - Black Scholes Options-Pricing Model, Assumptions (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average expected life in years	6 years	6 years	6 years
Dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected price volatility	68.76%	62.65%	73.00%
Risk-free interest rate	1.77%	0.56%	1.25%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected price volatility	78.79%	80.78%	76.78%
Risk-free interest rate	2.05%	1.70%	1.68%

Liquidity - Additional Informat

Liquidity - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Liquidity And Managements Plans [Line Items]
Cash	$ 21,195	$ 32,019	$ 83,560	$ 70,472
Net cash flows from operating activities	(32,451)	(53,982)	(3,732)
Stockholders' equity (deficit)	8,877	$ (17,665)	$ 31,696	$ 54,396
CRG [Member] | Line of Credit [Member]
Liquidity And Managements Plans [Line Items]
Additional borrowing capacity	$ 15,000

Accounts Payable and Accrued 46

Accounts Payable and Accrued Liabilities - Summary of Components of Accounts Payable and Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accounts payable	$ 12,236	$ 9,397
Accrued rebates	5,648	3,842
Accrued compensation and benefits	3,472	2,052
Accrued acquisition costs	2,311
Accrued returns	915
Accrued royalties	488	518
Accrued clinical trial costs	234	615
Accrued legal	216	490
Accrued manufacturing costs		200
Accrued sales and marketing costs		193
Accrued other	629	265
Total accounts payable and accrued expenses	$ 26,149	$ 17,572

Accounts payable and Accrued 47

Accounts payable and Accrued Liabilities - Additional Information (Detail) - Vendor	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounts Payable And Accrued Expenses [Line Items]
Number of vendors	3	2
Accounts Payable [Member] | Supplier Concentration Risk [Member]
Accounts Payable And Accrued Expenses [Line Items]
Percentage of amount due to major vendors accounts payable	39.00%	28.00%

Property and Equipment - Summar

Property and Equipment - Summarized Category of Fixed Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	$ 6,806	$ 6,681
Less accumulated depreciation	(3,028)	(2,451)
Total property, plant & equipment, net	3,778	4,230
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	5,428	4,476
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	399	464
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	169	202
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	44	53
Idle Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant & equipment, gross	$ 766	$ 1,486

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation	$ 693	$ 437	$ 329

Other Intangible Assets - Summa

Other Intangible Assets - Summary of Other Intangible Assets Net Consisting of Product Rights and Licenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 52,950	$ 10,950
Accumulated Amortization	(11,090)	(8,665)
Intangible Assets, net	41,860	2,285
Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	6,050	9,050
Accumulated Amortization	(4,881)	(7,052)
Intangible Assets, net	1,169	1,998
License and Distribution Rights [Member] | BELBUCA [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	45,000
Accumulated Amortization	(4,500)
Intangible Assets, net	40,500
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,900	1,900
Accumulated Amortization	(1,709)	(1,613)
Intangible Assets, net	$ 191	$ 287
Weighted average Useful Life	15 years
Weighted Average [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average Useful Life	10 years 2 months 30 days	10 years 11 months 12 days
Weighted Average [Member] | Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average Useful Life	1 year 2 months 16 days	9 years 1 month 10 days
Weighted Average [Member] | License and Distribution Rights [Member] | BELBUCA [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average Useful Life	8 years 6 months
Weighted Average [Member] | Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average Useful Life	6 months 14 days	1 year 10 months 2 days

Other Intangible Assets - Addit

Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense on other intangible assets	$ 5,425	$ 971	$ 970

Other Intangible Assets - Sched

Other Intangible Assets - Schedule Estimated Aggregate Future Amortization Expenses for Other Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
2,018	$ 5,157
2,019	5,157
2,020	4,547
2,021	4,500
2,022	4,500
Thereafter	17,999
Intangible Assets, net	$ 41,860	$ 2,285

License and Development Agree53

License and Development Agreements - Meda License, Development and Supply Agreements - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue Recognition, Milestone Method [Line Items]
Contract revenues	$ 21,194	$ 2,500	$ 41,759
U.S. [Member] | Milestones [Member]
Revenue Recognition, Milestone Method [Line Items]
Contract revenues			$ 1,000

License and Development Agree54

License and Development Agreements - Collegium License and Development Agreement - Additional Information (Detail) - Collegium License and Development Agreement [Member] $ in Millions	1 Months Ended
	Jun. 30, 2016USD ($)
Revenue Recognition, Milestone Method [Line Items]
Non-refundable payment received	$ 2.5
Execution term of license agreement	30 days

License and Development Agree55

License and Development Agreements - Endo License and Development Agreement - Additional Information (Detail) - USD ($)	1 Months Ended			12 Months Ended
	Jan. 31, 2017	Nov. 30, 2015	Feb. 28, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Oct. 31, 2015	Oct. 26, 2015
Revenue Recognition, Milestone Method [Line Items]
Potential payments upon filing and acceptance			$ 10,000,000
Potential milestone payment receivable upon regulatory approval								$ 50,000,000
Milestone payment upon regulatory approval deferred for future revenue recognition		$ 20,000,000
Patent extension starting period				2,020
Patent extension ending period				2,027
Royalty payment description				$50 million upon regulatory approval, earned in October 2015 and received in November 2015. Of the $50 million received in November 2015, $20 million related to a patent extension and was recorded as deferred revenue because all or a portion of such $20 million was contingently refundable to Endo if a third party generic product was introduced in the U.S. during the patent extension period from 2020 to 2027. However, due to the Company and Endo entering into a Termination Agreement on December 7, 2016 which terminated the BELBUCA® license to Endo effective January 6, 2017, the deferred $20 million was recognized as revenue during the nine months ended September 30, 2017 in the accompanying condensed consolidated statement of operations (see note 7, Business Combination and Asset Acquisition).
Deferred revenue from research and development activities				$ 799,000	$ 1,134,000	$ 909,000
Milestone payment, deferred revenue				0	1,700,000
Endo Agreement [Member]
Revenue Recognition, Milestone Method [Line Items]
Deferred revenue from research and development activities				0	$ 0	900,000
Endo Agreement [Member] | BELBUCA [Member]
Revenue Recognition, Milestone Method [Line Items]
Potential milestone payment receivable upon regulatory approval									$ 50,000,000
Milestone payment upon regulatory approval deferred for future revenue recognition	$ 20,000,000
Deferred revenue from research and development activities							$ 6,000,000
Milestone payment, deferred revenue		$ 20,000,000
Milestone payment recognized						$ 30,000,000
Endo Agreement [Member]
Revenue Recognition, Milestone Method [Line Items]
Deferred revenue refund payment				$ 20,000,000
Termination agreement date				Dec. 7, 2016
License termination effective date				Jan. 6, 2017

Business Combination and BELB56

Business Combination and BELBUCA Acquisition - Additional Information (Detail) - USD ($)	Jan. 06, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Income tax benefit		$ 15,972,000	$ 0	$ 0
Bargain purchase gain		$ 27,336,000
BELBUCA [Member]
Business Acquisition [Line Items]
Useful life of equipment		7 years
Deferred tax liability	$ (15,972,000)
Income tax benefit		$ 16,000,000
Bargain purchase gain	$ 27,336,000	$ 27,300,000
BELBUCA [Member] | License and Distribution Rights [Member]
Business Acquisition [Line Items]
Amortization of intangible asset		10 years
Endo Agreement [Member]
Business Acquisition [Line Items]
Termination agreement date		Dec. 7, 2016
License termination effective date		Jan. 6, 2017
Potential milestone payments on intellectual property rights		$ 5,000,000
Term of Endo Agreement		2 years
Contract termination claims, description		Together with the Asset Purchase Price, pursuant to the terms of the Termination Agreement, the Company will also pay to Endo a fee in the amount of $5 million in consideration for (i) Endo's agreement not to compete for a period of two years from the closing date of the termination agreement and (ii) Endo's waiver of its right to sell product for twelve months following the closing of the termination agreement.

Business Combination and BELB57

Business Combination and BELBUCA Acquisition - Summary of Asset Purchase Price and Estimated Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Jan. 06, 2017	Dec. 31, 2017
Asset purchase price:
Deferred cash consideration to Endo		$ 5,853
Estimated fair value of assets acquired:
Bargain purchase gain		(27,336)
BELBUCA [Member]
Asset purchase price:
Deferred cash consideration to Endo	$ 7,536
Total asset purchase price	7,536
Estimated fair value of assets acquired:
Current BELBUCA® product inventory and work-in process	5,412
BELBUCA®-related manufacturing equipment	432
License and distribution rights intangible assets	45,000
Deferred tax liability	(15,972)
Amount attributable to assets acquired	34,872
Bargain purchase gain	$ (27,336)	$ (27,300)

Business Combination and BELB58

Business Combination and BELBUCA Acquisition - Summary of Proforma Impact of Acquisition (Detail) - BELBUCA [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)$ / shares
Business Acquisition [Line Items]
Revenue | $	$ 25,010
Net loss | $	$ (201,769)
Pro forma net loss per common share
Basic | $ / shares	$ (3.76)
Diluted | $ / shares	$ (3.76)

License Obligations - Evonik De

License Obligations - Evonik Definitive Development and Exclusive License Option Agreement - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017Agreement
Definitive Development and Exclusive License Option Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of license agreements granted	2

Other License Agreements and 60

Other License Agreements and Acquired Product Rights - Additional Information (Detail) $ in Thousands	Dec. 07, 2016	Oct. 07, 2010USD ($)	Mar. 31, 2018CAD ($)	Oct. 31, 2017CAD ($)	Aug. 31, 2017CAD ($)	Aug. 31, 2015USD ($)	Sep. 30, 2013USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Jul. 12, 2017CAD ($)
Collaborative Arrangement, Product [Member] | Purdue Pharma [Member] | BELBUCA [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Upfront and potential milestones payable											$ 1,500,000
Milestone based payments received				$ 1,000,000	$ 500,000
Collaborative Arrangement, Product [Member] | Purdue Pharma [Member] | BELBUCA [Member] | Maximum [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Upfront and potential milestones payable											$ 4,500,000
Collaborative Arrangement, Product [Member] | Subsequent Event [Member] | Purdue Pharma [Member] | BELBUCA [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Milestone based payments received			$ 1,000,000
Distribution Agreement [Member] | BELBUCA [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Initial Term	3 years
Renewal term option for one year	2 years
Renewal term option for two years	1 year
Kunwha License Agreement [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Expiration date of the agreement						Aug. 31, 2015		Jul. 23, 2027
Upfront payment								$ 300
Up-front payment net of tax								250
Milestone payment received						$ 300
Kunwha License Agreement [Member] | Maximum [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Milestone payments								1,300
Milestone payments net of tax								1,100
TTY License and Supply Agreement [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Upfront payment		$ 300
Milestone payment received							$ 300	$ 1,200	$ 900	$ 0
Term of the agreement								15 years
TTY License and Supply Agreement [Member] | Maximum [Member]
Other License Agreements And Acquired Product Rights [Line Items]
Milestone payments		$ 1,300

Note Payable (MidCap Loan) - Ad

Note Payable (MidCap Loan) - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Feb. 21, 2017	Dec. 31, 2017	Dec. 26, 2017	May 29, 2015
MidCap Financial Trust [Member] | Secured Loan Facility [Member]
Debt Instrument [Line Items]
Secured loan facility				$ 30
MidCap Financial Trust [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Net proceeds in aggregate amount	$ 29.4
Number of warrants to purchase common stock		84,986
Exercise price of warrants to purchase common stock		$ 3.53
Class Of Warrant Or Rights Date From Which Warrants Or Rights Expired		2021-05
MidCap Financial Trust [Member] | Secured Debt [Member] | Interest Expense [Member]
Debt Instrument [Line Items]
Deferred loan costs expensed		$ 0.7
CRG [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
License termination effective date		Feb. 21, 2017
Number of warrants to purchase common stock	1,701,583		349,452
Exercise price of warrants to purchase common stock	$ 2.38		$ 3.42

Term Loan Agreement (CRG) - Add

Term Loan Agreement (CRG) - Additional Information (Detail)	Dec. 26, 2017USD ($)$ / sharesshares	Feb. 21, 2017USD ($)Warrant$ / sharesshares
Debt Instrument [Line Items]
Remainder of borrowings		$ 13,700,000
CRG [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Borrowings outstanding		45,000,000
Additional borrowing capacity upon milestone achievement		30,000,000
Second draw borrowing capacity upon milestone achievement		$ 5,000,000
Loan agreement term		6 years
Loan agreement interest only term		3 years
Loan agreement interest only term threshold		4 years
Agreement maturity date		Dec. 31, 2022
Interest on borrowings		12.50%
Interest on borrowings, interest only period percentage		3.50%
Effective interest on borrowings		9.00%
Final payment fee rate		9.00%
Prepayment period of outstanding principal and accrued unpaid interest		5 years
Prepayment fee after		$ 0
Additional interest rate		4.00%
Number of warrants | Warrant		5
Warrants issued to purchase shares of common stock | shares	349,452	1,701,583
Warrants exercise price | $ / shares	$ 3.42	$ 2.38
CRG [Member] | Tranche One [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Additional borrowing capacity upon milestone achievement		$ 15,000,000
CRG [Member] | Tranche Two [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Additional borrowing capacity upon milestone achievement		$ 15,000,000
Second draw gross proceeds	$ 15,000,000

Term Loan Agreement (CRG) - Fut

Term Loan Agreement (CRG) - Future Maturities of CRG Obligation (Detail) - CRG [Member] - Line of Credit [Member] $ in Thousands	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
2,018	$ 0
2,019	0
2,020	20,054
2,021	20,054
2,022	20,054
Total maturities	60,162
Unamortized discount and loan costs	(12,502)
Total CRG obligation	$ 47,660

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017Segment
Segment Reporting [Abstract]
Number of reportable segment	1

Segment Reporting - Summary of

Segment Reporting - Summary of Net Sales by Product (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Sales Information [Line Items]
Net product sales	$ 34,922	$ 8,266	$ 4,157
BELBUCA [Member]
Sales Information [Line Items]
Net product sales	26,980	0
BUNAVAIL [Member]
Sales Information [Line Items]
Net product sales	$ 7,942	$ 8,266	$ 4,157

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	Dec. 31, 2017	Dec. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax [Line Items]
Federal statutory income tax rate				34.00%	34.00%	34.00%
Tax Cuts and Jobs Act, Accounting Complete				false
Income tax benefit				$ 33,100,000
State and local income taxes				2.01%	2.88%	3.45%
Income tax expense (benefit)				$ (15,972,000)	$ 0	$ 0
Minimum percentage of likelihood of realization of deferred tax assets				50.00%
Change in valuation allowance (independent of the impact of the 2017 Tax Act)				$ 4,400,000
Uncertain income tax positions	$ 0			0
State and Local Jurisdiction [Member]
Income Tax [Line Items]
Operating Loss carry forward	292,000,000			$ 292,000,000
Operating loss carry forward expiration term				Dec. 31, 2030
State and Local Jurisdiction [Member] | North Carolina [Member]
Income Tax [Line Items]
State and local income taxes		4.00%		3.00%
Income tax benefit				$ 1,700,000
Domestic Country [Member]
Income Tax [Line Items]
Operating Loss carry forward	263,000,000			263,000,000
Net operating loss used to offset taxable income	$ 1,500,000			$ 1,500,000
Domestic Country [Member] | Minimum [Member]
Income Tax [Line Items]
Operating loss carry forward expiration term	Dec. 31, 2024
Domestic Country [Member] | Maximum [Member]
Income Tax [Line Items]
Operating loss carry forward expiration term	Dec. 31, 2037
Scenario, Plan [Member]
Income Tax [Line Items]
Federal statutory income tax rate			21.00%

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Federal statutory income (benefit) tax rate	(34.00%)	(34.00%)	(34.00%)
2017 Tax Act, net deferred tax remeasurement	(626.73%)
State taxes, net of federal benefit	(2.01%)	(2.88%)	(3.45%)
Stock compensation	(5.18%)	0.61%
Permanent differences-other	(13.39%)	1.00%	4.66%
Research and development ("R&D") credit	5.54%	(0.98%)	(0.95%)
Valuation release for bargain purchase gain	(302.23%)
Other	(1.36%)	0.47%	(0.64%)
Decrease (increase) in valuation allowance	709.88%	35.78%	34.38%
Federal statutory income tax rate, Total	(302.23%)	(0.00%)	(0.00%)
North Carolina [Member]
Income Taxes [Line Items]
North Carolina tax rate change	(32.75%)

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Deferred revenue		$ 7,377
Basis difference in equipment	$ (587)	(1,084)
Basis difference in intangibles	(8,288)	1,201
Accrued liabilities and other	654	550
R&D credit	11,882	11,589
AMT credit	79	79
Stock options	6,115	5,697
Net operating loss carry-forward	61,660	83,621
Gross, Deferred Tax Assets	71,515	109,030
Less: valuation allowance	(71,515)	(109,030)
Net of Valuation Allowance	$ 0	$ 0

Stockholders' Equity - Addition

Stockholders' Equity - Additional information (Detail) - USD ($)	Dec. 16, 2015	Jul. 02, 2015	Jul. 11, 2011	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2012	Feb. 28, 2017	Mar. 31, 2016	Dec. 31, 2014	Dec. 03, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Company employees, directors and affiliates stock option exercised				202,519	147,425	235,480
Proceeds from common stock				$ 439,000	$ 297,000	$ 755,000
Preferred Stock, par value				$ 0.001	$ 0.001
Authorized shares of preferred stock				5,000,000	5,000,000
Number of RSUs vested				363,701
Common stock authorized beginning balance				75,000,000	75,000,000
Weighted average grant date fair value of options granted				$ 1.46	$ 1.75	$ 4.99
Number of options granted in period with exercise price below market price				0	0	0
Unrecognized compensation cost related to non-vested share-based compensation awards granted				$ 5,500,000
Unrecognized compensation cost related to non-vested share-based compensation awards granted year				3 years
Options outstanding				2,712,954	3,468,991	3,397,529				3,196,100
Fair value of warrants				$ 6,000,000
2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares of common stock authorized				7,100,000
2011 Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized beginning balance				11,050,000
2011 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized beginning balance				18,150,000
Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock options outstanding and exercisable			890,693
Term that options may be awarded			10 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity instruments awarded in period				2,357,315
Fair market value of RSUs granted				$ 4,700,000
Vesting period of options				3 years
Restricted Stock Units (RSUs) [Member] | LTIP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity instruments awarded in period				0	0	35,000
Restricted stock units ("RSUs") issued to directors and key employees				1,078,000			978,000
Restricted stock units reserved for future officers						100,000
RSU's Vested per performance criteria during period				8 years
Number of RSUs vested				9,958	13,347	21,356
Series A Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized shares of preferred stock				2,290,700
Series A Preferred shares issued				2,093,155							2,709,300
Liquidation, dissolution or winding up, holders of the Series A Preferred per share payment											$ 0.001
Series A Preferred stock converted				0	0	45,845
Employees and Directors Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Company employees, directors and affiliates stock option exercised				200,000	100,000	200,000
Proceeds from common stock				$ 400,000	$ 300,000	$ 800,000
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding				84,986
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Company's securities for shelf registration		$ 150,000,000
Universal shelf registration amount, maximum		$ 40,000,000
Company employees, directors and affiliates stock option exercised				202,519	147,426	223,923
MidCap Financial Trust [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock					84,986
Exercise price of warrants					$ 3.53
Fair value of warrants					$ 50,000
CRG [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock				349,451				1,701,583
Exercise price of warrants				$ 3.42				$ 2.38
Fair value of warrants				$ 1,500,000				$ 4,500,000
CRG [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding				2,051,034
Dr. Andrew Finn [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period shares upon employee retirement	513,221
Issuance of common stock upon employee retirement									150,000
Employee retirement date				Dec. 31, 2015
Directors and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity instruments awarded in period				956,675
Fair market value of shares granted				$ 1,400,000
Term of options granted period				10 years
Directors and Employees [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's Vested per performance criteria during period				1 year
Directors and Employees [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's Vested per performance criteria during period				3 years

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Restricted Stock Activity (Detail) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Shares, Outstanding at beginning of period	4,584,297
Number of Shares, Granted	2,357,315
Number of Restricted Shares, Vested	(1,568,042)
Number of Restricted Shares, Forfeitures	(666,675)
Number of Restricted Shares, Outstanding at end of period	4,706,895
Weighted Average Fair Market Value Per RSU, Outstanding at beginning of period | $ / shares	$ 7.29
Weighted Average Fair Market Value Per RSU, Vested | $ / shares	2.17
Weighted Average Fair Market Value Per RSU, Forfeitures | $ / shares	2.71
Weighted Average Fair Market Value Per RSU, Outstanding at end of period | $ / shares	$ 5.20
Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	1,640,000
Weighted Average Fair Market Value Per RSU, Granted | $ / shares	$ 1.85
Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	162,315
Weighted Average Fair Market Value Per RSU, Granted | $ / shares	$ 2.80
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	555,000
Weighted Average Fair Market Value Per RSU, Granted | $ / shares	$ 2.10

Stockholders' Equity - Summar71

Stockholders' Equity - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding at beginning of period	3,468,991	3,397,529	3,196,100
Number of Shares, Granted	960,175
Number of Shares, Exercised	(202,519)	(147,425)	(235,480)
Number of Shares, Forfeitures	(1,510,193)	(434,486)	(247,720)
Number of Shares, Outstanding at end of period	2,712,954	3,468,991	3,397,529
Weighted Average Exercise Price Per Share, Outstanding at beginning of period	$ 4.14	$ 5.42	$ 4.32
Weighted average Exercise Price Per Share, Exercised	2.17	2.01	3.52
Weighted Average Exercise Price Per Share, Forfeitures	5.13	13.17	12.65
Weighted Average Exercise Price Per Share, Outstanding at end of period	$ 2.98	$ 4.14	$ 5.42
Aggregate Intrinsic Value, Outstanding at beginning of period	$ 0	$ 3,124	$ 22,881
Aggregate Intrinsic Value, Granted	$ 0	$ 0	$ 0
Aggregate Intrinsic Value, Outstanding at end of period	$ 1,190	$ 0	$ 3,124
Officers and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	83,658	95,000
Weighted Average Exercise Price Per Share, Granted	$ 2.64	$ 2.34
Others [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	873,017	558,373	684,629
Weighted Average Exercise Price Per Share, Granted	$ 1.96	$ 3.12	$ 8.14

Stockholders' Equity - Summar72

Stockholders' Equity - Summary of Stock Options Outstanding (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding	2,712,954
Aggregate Intrinsic Value	$ 1,190	$ 0	$ 3,124	$ 22,881
$1.00 - 5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	$ 1
Range of Exercise Prices, maximum	$ 5
Number Outstanding	2,192,695
Weighted Average Remaining Contractual Life (Years)	5 years 6 months 10 days
Weighted Average Exercise Price	$ 2.72
$5.01 - 10.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	5.01
Range of Exercise Prices, maximum	$ 10
Number Outstanding	430,149
Weighted Average Remaining Contractual Life (Years)	5 years 4 months 17 days
Weighted Average Exercise Price	$ 6.29
$ 10.01 - 15.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	10.01
Range of Exercise Prices, maximum	$ 15
Number Outstanding	48,358
Weighted Average Remaining Contractual Life (Years)	7 years 1 month 20 days
Weighted Average Exercise Price	$ 13.13
$15.01 - 20.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	15.01
Range of Exercise Prices, maximum	$ 20
Number Outstanding	41,500
Weighted Average Remaining Contractual Life (Years)	6 years 9 months
Weighted Average Exercise Price	$ 16.27

Stockholders' Equity - Summar73

Stockholders' Equity - Summary of Stock Options Exercisable (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Exercisable | shares	1,822,218
Aggregate Intrinsic Value | $	$ 561
$1.00 - 5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	$ 1
Range of Exercise Prices, maximum	$ 5
Number Exercisable | shares	1,400,022
Weighted Average Remaining Contractual Life (Years)	3 years 5 months 23 days
Weighted Average Exercise Price	$ 3.04
$5.01 - 10.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	5.01
Range of Exercise Prices, maximum	$ 10
Number Exercisable | shares	345,257
Weighted Average Remaining Contractual Life (Years)	5 years 5 months 5 days
Weighted Average Exercise Price	$ 6.28
$ 10.01 - 15.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	10.01
Range of Exercise Prices, maximum	$ 15
Number Exercisable | shares	35,439
Weighted Average Remaining Contractual Life (Years)	7 years 1 month 16 days
Weighted Average Exercise Price	$ 13.15
$15.01 - 20.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum	15.01
Range of Exercise Prices, maximum	$ 20
Number Exercisable | shares	41,500
Weighted Average Remaining Contractual Life (Years)	6 years 9 months
Weighted Average Exercise Price	$ 16.27

Stockholders' Equity - Summar74

Stockholders' Equity - Summary of Non-Vested Stock Options (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Nonvested at beginning of period	829,431
Nonvested, Shares, Granted	960,175
Nonvested, Shares, Vested	(363,701)
Nonvested, Shares, Forfeited	(540,421)
Nonvested at end of period	885,484
Weighted Average Grant Date Fair Value, Nonvested at December 31, 2017 | $ / shares	$ 2.70
Nonvested at December 31, 2017, Aggregate Intrinsic Value | $	$ 629

Stockholders' Equity - Summar75

Stockholders' Equity - Summary of Allocated Stock-based Compensation Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 1.6	$ 2.5	$ 4.2
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 13.2	$ 12.4	$ 10

Earnings per Common Share - Rec

Earnings per Common Share - Reconciliation of Numerators and Denominators of Basic and Diluted Earnings Per Common Share Computations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Basic:
Net income (loss) attributable to common stockholders													$ 5,285	$ (67,138)	$ (37,672)
Weighted average common shares outstanding													55,355,802	53,679,134	52,384,876
Basic earnings (loss) per common share	$ (0.31)	$ (0.21)	$ (0.27)	$ 0.89	$ (0.29)	$ (0.30)	$ (0.31)	$ (0.35)	$ 0.20	$ (0.39)	$ (0.37)	$ (0.16)	$ 0.10	$ (1.25)	$ (0.72)
Effect of dilutive securities:
Net income (loss) attributable to common stockholders	$ (16,210)	$ (11,951)	$ (14,879)	$ 48,325	$ (15,942)	$ (15,977)	$ (16,486)	$ (18,733)	$ 10,171	$ (20,439)	$ (19,211)	$ (8,193)	$ 5,285	$ (67,138)	$ (37,672)
Adjustment to income for dilutive options and warrants													0	0	0
Net income (loss), diluted, Total													$ 5,285	$ (67,138)	$ (37,672)
Weighted average common shares outstanding													55,355,802	53,679,134	52,384,876
Effect of dilutive options and warrants													1,046,677
Diluted weighted average common shares outstanding													56,402,479	53,679,134	52,384,876
Diluted earnings (loss) per common share	$ (0.30)	$ (0.21)	$ (0.27)	$ 0.87	$ (0.29)	$ (0.30)	$ (0.31)	$ (0.35)	$ 0.20	$ (0.39)	$ (0.37)	$ (0.16)	$ 0.09	$ (1.25)	$ (0.72)

Earnings per Common Share - Add

Earnings per Common Share - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Securities excluded from computation of diluted earnings per share	6,531,346	10,228,929	9,788,838

Earnings per Common Share - Sch

Earnings per Common Share - Schedule of Total Outstanding Options, RSUs and Warrants (Detail) - shares	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Options, RSUs, warrants and convertible preferred stock to purchase Common Stock	9,555,869	10,228,929	9,788,838

Retirement Plan - Additional In

Retirement Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Employers' sponsors contribution retirement plan	90.00%
Contribution to retirement plan, percentage of employee contribution	100.00%
Employers' sponsors contribution retirement plan amount	$ 0.5	$ 0.4	$ 0.2
Maximum [Member]
Pension Plans, Postretirement and Other Employee Benefits [Line Items]
Percentage of employee contribution to retirement plan	5.00%

Retirement Agreement - Addition

Retirement Agreement - Additional Information (Detail)	Jan. 19, 2018USD ($)	Feb. 28, 2018shares	Jan. 31, 2018USD ($)shares	Sep. 30, 2017USD ($)	Dec. 31, 2018	Dec. 31, 2017USD ($)$ / hshares	Dec. 31, 2012shares	Apr. 01, 2018USD ($)
Restricted Stock Units (RSUs) [Member] | LTIP [Member]
Defined Benefit Plan Disclosure [Line Items]
Issuance of shares | shares						1,078,000	978,000
Sirgo Retirement Agreement [Member] | Chief Executive Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash payment paid				$ 800,000
Sirgo Retirement Agreement [Member] | Chief Executive Officer [Member] | LTIP [Member]
Defined Benefit Plan Disclosure [Line Items]
Vesting rights, percentage						100.00%
Change in control period considered after retirement date						12 months
Vasisht Retirement Agreement [Member] | Chief Technology Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash payment granted						$ 330,000
Number of equal installments						2
Retirement agreement description						if a Change of Control (as defined in the Vasisht Employment Agreement) occurs before July 1, 2018, Dr. Vasisht will be entitled to the cash payments provided for in Paragraph 4(d) of the Vasisht Employment Agreement (namely, a cash payment equal to: (A) Dr. Vasisht’s annual base salary plus an amount equal to fifty percent (50%) of his such salary multiplied by (B) 1.5), but less the separation payments made under the Vasisht Retirement Agreement
Consulting rate | $ / h						200
Consulting period						12 months
Vasisht Retirement Agreement [Member] | Chief Technology Officer [Member] | LTIP [Member]
Defined Benefit Plan Disclosure [Line Items]
Vesting rights, percentage						100.00%
Vasisht Retirement Agreement [Member] | Chief Technology Officer [Member] | Scenario, Forecast [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash payment granted								$ 165,000
Vasisht Retirement Agreement [Member] | Chief Technology Officer [Member] | Scenario, Forecast [Member] | Performance Based Restricted Stock Units Rsu [Member]
Defined Benefit Plan Disclosure [Line Items]
Vesting rights, percentage					60.00%
Vesting rights, percentage forfeited					40.00%
Subsequent Event [Member] | Sirgo Retirement Agreement [Member] | Chief Executive Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash payment paid			$ 800,000
Subsequent Event [Member] | Sirgo Retirement Agreement [Member] | Chief Executive Officer [Member] | Performance Based Restricted Stock Units Rsu [Member]
Defined Benefit Plan Disclosure [Line Items]
Issuance of shares | shares			795,730
Subsequent Event [Member] | Sirgo Retirement Agreement [Member] | Chief Executive Officer [Member] | Time Based Restricted Stock Units R S U [Member]
Defined Benefit Plan Disclosure [Line Items]
Issuance of shares | shares			250,000
Subsequent Event [Member] | Vasisht Retirement Agreement [Member] | Chief Technology Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash payment paid	$ 165,000,000
Cash payment paid for deferred raise	$ 20,000
Subsequent Event [Member] | Vasisht Retirement Agreement [Member] | Chief Technology Officer [Member] | Restricted Stock Units (RSUs) [Member]
Defined Benefit Plan Disclosure [Line Items]
Issuance of shares | shares		309,162
Subsequent Event [Member] | Vasisht Retirement Agreement [Member] | Chief Technology Officer [Member] | Restricted Stock Units (RSUs) [Member] | 2017 Equity Award [Member]
Defined Benefit Plan Disclosure [Line Items]
Issuance of shares | shares		198,129

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Contingencies And Commitments [Line Items]
Lease expense		$ 300,000	$ 300,000	$ 300,000
Lease term		89 months
CDC [Member]
Contingencies And Commitments [Line Items]
Royalties received		$ 20,000
Granted royalty on sales of the next BEMA product		1.00%
Net sales of next BEMA Product		$ 7,500,000
Minimum [Member] | CDC [Member]
Contingencies And Commitments [Line Items]
Royalties received		$ 375,000
Opioid PMR Consortium [Member]
Contingencies And Commitments [Line Items]
Participation expense	$ 4,300,000

Commitments and Contingencies82

Commitments and Contingencies - Future Minimum Commitment on the Remaining Operating Lease (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 341
2,019	351
2,020	360
2,021	370
2,022	219
Total operating lease	$ 1,641

Selected Quarterly Results (U83

Selected Quarterly Results (Unaudited) - Selected Quarterly Results (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Selected Quarterly Financial Information [Abstract]
Revenue	$ 12,510	$ 11,253	$ 8,744	$ 29,478	$ 3,931	$ 3,571	$ 5,004	$ 3,040	$ 32,209	$ 1,235	$ 1,733	$ 13,054	$ 61,985	$ 15,546	$ 48,231
Gross profit	7,275	6,808	4,573	23,833	1,631	1,257	910	490	29,552	(464)	(888)	11,930
Income (loss) from operations	(14,291)	(10,045)	(12,987)	7,903	(15,200)	(15,199)	(15,594)	(17,942)	10,954	(19,652)	(18,681)	(7,800)	(29,420)	(63,935)	(35,179)
Net income (loss)	$ (16,210)	$ (11,951)	$ (14,879)	$ 48,325	$ (15,942)	$ (15,977)	$ (16,486)	$ (18,733)	$ 10,171	$ (20,439)	$ (19,211)	$ (8,193)	$ 5,285	$ (67,138)	$ (37,672)
Basic income (loss) per share	$ (0.31)	$ (0.21)	$ (0.27)	$ 0.89	$ (0.29)	$ (0.30)	$ (0.31)	$ (0.35)	$ 0.20	$ (0.39)	$ (0.37)	$ (0.16)	$ 0.10	$ (1.25)	$ (0.72)
Diluted income (loss) per share	$ (0.30)	$ (0.21)	$ (0.27)	$ 0.87	$ (0.29)	$ (0.30)	$ (0.31)	$ (0.35)	$ 0.20	$ (0.39)	$ (0.37)	$ (0.16)	$ 0.09	$ (1.25)	$ (0.72)

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts and Reserves (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Valuation Allowance for Deferred Tax Assets [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of the period	$ 109,030	$ 84,960	$ 72,061
Charged to income	(37,515)	24,070	12,899
Balance at end of the period	71,515	109,030	84,960
Allowance for Rebates [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of the period	3,842	4,470	939
Charged to income	17,236	(1,204)	2,118
Charged to other accounts	(132)	11,501	6,360
Deductions	(15,298)	(10,925)	(4,947)
Balance at end of the period	5,648	3,842	4,470
Allowance for Price Adjustments and Chargebacks [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of the period	602	383	400
Charged to income	6,738	36	(2,118)
Charged to other accounts	(3)	1,711	3,259
Deductions	(3,412)	(1,528)	(1,158)
Balance at end of the period	3,925	$ 602	383
Allowance for inventory obsolescence [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Charged to income	243		213
Charged to other accounts			$ (213)
Balance at end of the period	$ 243